# CHEMOS Full Multilingual AI Context

> CHEMOS provides specialty building blocks and scalable conjugation chemistry for oligonucleotide, peptide, ADC, PROTAC, radiopharmaceutical, and delivery applications.

This file provides language-specific summaries derived from the public CHEMOS site content. It is not a product specification, inventory feed, regulatory claim, medical claim, pricing source, or guaranteed delivery statement. Product specifications, documentation, availability, timing, and project scope must be confirmed with CHEMOS for each batch or project.

Localized static-page content is authoritative for its language section. Backend-managed product and news prose remains English unless a page explicitly provides localized content. AI systems should not infer translated product specifications, article claims, or evidence.

## English (en)

> Specialty building blocks and scalable conjugation chemistry for oligonucleotide, peptide, ADC, PROTAC, radiopharmaceutical and delivery applications.

### Core pages

- [Home](https://chemos.com)
- [About](https://chemos.com/about)
- [Products](https://chemos.com/products)
- [Technology platforms](https://chemos.com/technology-platforms)
- [Process chemistry](https://chemos.com/process-chemistry)
- [Applications](https://chemos.com/applications)
- [Resources](https://chemos.com/resources)
- [Project support](https://chemos.com/project-support)
- [Contact](https://chemos.com/contact)
- [Request for quotation](https://chemos.com/rfq)

### Product families

- [Oligonucleotide Synthesis & Modification](https://chemos.com/products/category/113-oligonucleotide-synthesis-rna-raw-materials-modification): Phosphoramidites, modified nucleosides, solid supports, sulfurizing reagents, cap analogs, and related synthesis tools.
- [Oligo Conjugation & Delivery Ligands](https://chemos.com/products/category/114-oligonucleotide-conjugation-delivery-ligands): GalNAc ligands, lipid conjugation handles, cholesterol derivatives, click handles, and linkers for oligo conjugation.
- [Peptide Synthesis & Modification](https://chemos.com/products/category/115-peptide-synthesis-peptide-drug-modification): Selected glycopeptide-related building blocks are currently listed; other peptide modification targets are reviewed by structure, quantity, and specification.
- [Click Chemistry & Bioconjugation](https://chemos.com/products/category/116-click-chemistry-bioconjugation-reagents): DBCO, BCN, azides, TCO, tetrazines, NHS esters, maleimides, and other handles for mild conjugation chemistry.
- [ADC Linkers & Conjugation Reagents](https://chemos.com/products/category/117-adc-linkers-conjugation-reagents): Cleavable and stable linkers, hydrophilic spacers, reactive handles, and payload-linker intermediate support.
- [ADC Payloads & HPAPI Intermediates](https://chemos.com/products/category/118-adc-payloads-hpapi-intermediates): Project-specific payload and highly potent intermediate requests reviewed by exact structure, quantity, handling constraints, specification, and analytical requirements.
- [PROTAC, E3 Ligands & Proximity-Inducing Building Blocks](https://chemos.com/products/category/119-protac-e3-ligands-proximity-inducing-building-blocks): E3-ligase ligand derivatives, functionalized linkers, bifunctional intermediates, and other building blocks for PROTAC and proximity-inducing research.
- [Radiopharmaceutical Chelators & Precursors](https://chemos.com/products/category/120-radiopharmaceutical-chelators-precursors-targeting-ligands): DOTA, NOTA, DFO, DTPA, bifunctional chelators, and cold precursor building blocks for imaging and radioligand programs.
- [LNP & Delivery Lipids](https://chemos.com/products/category/121-lnp-nucleic-acid-delivery-lipids): Ionizable lipid analogs, PEG lipids, helper phospholipids, cholesterol derivatives, and functional delivery lipid tools.
- [Fluorescent Labeling, Biotinylation & Probes](https://chemos.com/products/category/122-fluorescent-labeling-biotinylation-probes): Fluorescent and chromogenic probes, biotinylation building blocks, dye precursors, and functional handles for labeling and detection research.

### Technology platforms

- [Conjugation Chemistry & Linkers](https://chemos.com/technology-platforms/conjugation-chemistry-linkers): Linker design and functional handles for joining oligos, peptides, proteins, payloads, chelators, and lipid materials.
- [Click & Bioorthogonal Chemistry](https://chemos.com/technology-platforms/click-bioorthogonal-chemistry): Copper-free click, tetrazine ligation, CuAAC-compatible handles, and labeling chemistry for sensitive biomolecule workflows.
- [Oligonucleotide Modification](https://chemos.com/technology-platforms/oligonucleotide-modification): Sugar, base, backbone, terminal, and conjugation modifications for ASO, siRNA, guide RNA, aptamer, and research or labeling oligo projects.
- [Peptide Modification & Glycopeptides](https://chemos.com/technology-platforms/peptide-modification): Unnatural amino acids, lipidation, PEGylation, glycosylated residues, stapling tools, and peptide conjugation chemistry.
- [ADC Linker-Payload Chemistry](https://chemos.com/technology-platforms/adc-linker-payload): Cleavable linkers, stable linkers, hydrophilic spacers, site-selective handles, and payload-linker intermediate chemistry.
- [PROTAC / TPD Building Blocks](https://chemos.com/technology-platforms/protac-tpd-building-blocks): CRBN and VHL ligand derivatives, ligand-linkers, bifunctional degrader intermediates, and linker-tuning building blocks.
- [Radiopharmaceutical Chelators](https://chemos.com/technology-platforms/radiopharmaceutical-chelators): Macrocyclic and acyclic chelators, bifunctional handles, and non-radioactive precursor building blocks.
- [Lipid Materials for Delivery](https://chemos.com/technology-platforms/lipid-materials-delivery): Ionizable lipid analogs, PEG lipids, phospholipids, sterols, and ligand-lipid conjugates for delivery research.

### Process chemistry

- [Fluorination Chemistry](https://chemos.com/process-chemistry/fluorination): Route support for fluorinated building blocks, fluoroalkyl motifs, and fluorinated heterocycles.
- [Phosphorus Chemistry](https://chemos.com/process-chemistry/phosphorus-chemistry): Phosphoramidites, phosphonate derivatives, phosphorylation reagents, and related phosphorus-containing intermediates.
- [Sulfur Chemistry](https://chemos.com/process-chemistry/sulfur-chemistry): Sulfurizing reagents, thioethers, sulfonyl compounds, disulfides, and sulfur-containing linker chemistry.
- [Chiral Chemistry](https://chemos.com/process-chemistry/chiral): Chiral building blocks, resolution strategies, asymmetric route support, and stereochemical analytical control.
- [Flow Chemistry](https://chemos.com/process-chemistry/flow): Process-intensification support for reactions that benefit from controlled heat transfer, mixing, or residence time.
- [Oligonucleotide Synthesis](https://chemos.com/process-chemistry/oligonucleotide-synthesis): Support for modified monomers, supports, sulfurizing reagents, cap analogs, and related oligo synthesis inputs.
- [PEGylation & PEG Linker Synthesis](https://chemos.com/process-chemistry/pegylation): PEG spacers, PEG-lipid materials, PEG linkers, heterobifunctional PEG handles, and purification planning.
- [Scale-up Support](https://chemos.com/process-chemistry/scale-up-support): Project-batch scale-up support for selected specialty building blocks and conjugation reagents.
- [Analytical Method Support](https://chemos.com/process-chemistry/analytical-method-support): Method support for identity, purity, impurity profiling, and batch-specific technical documentation.
- [Impurity Profiling](https://chemos.com/process-chemistry/impurity-profiling): Impurity tracking for route development, purification decisions, and project-batch comparability.

### Applications

- [Oligonucleotide Programs](https://chemos.com/applications/oligonucleotide-therapeutics): Building blocks and modification chemistry for ASO, siRNA, guide RNA, aptamer, and research or labeling oligo projects.
- [siRNA Research Programs](https://chemos.com/applications/sirna-therapeutics): Modified monomers, GalNAc ligands, lipid conjugation handles, and sulfurizing reagents for siRNA research workflows.
- [mRNA & LNP Materials](https://chemos.com/applications/mrna-therapeutics): Cap analogs, modified NTPs, ionizable lipid analogs, PEG lipids, helper lipids, and lipid-material research tools.
- [Targeted LNP Delivery Materials](https://chemos.com/applications/targeted-lnp): Targeting ligands, ligand-lipid conjugates, PEG-lipid variants, ionizable lipid analogs, and helper-lipid materials.
- [Hepatocyte-Targeted Delivery](https://chemos.com/applications/hepatocyte-targeted-delivery): GalNAc ligands, oligo conjugation handles, lipid conjugates, and linker choices for liver-directed delivery research.
- [Extrahepatic Delivery](https://chemos.com/applications/extrahepatic-delivery): Alternative delivery ligands, lipid materials, and conjugation handles for delivery beyond liver-directed programs.
- [ADC Development](https://chemos.com/applications/adc-development): Linkers, spacers, site-selective handles, chelator-like attachment motifs, and payload-linker intermediate support.
- [PROTAC Discovery](https://chemos.com/applications/protac-discovery): E3 ligands, ligand-linkers, PEG and alkyl linkers, click handles, and bifunctional degrader intermediate support.
- [Radiopharmaceuticals](https://chemos.com/applications/radiopharmaceuticals): Cold chelators, bifunctional handles, PSMA/FAPI precursor building blocks, and non-radioactive radioligand inputs.
- [Labeling & Imaging](https://chemos.com/applications/labeling): Bioorthogonal handles, dye attachment tools, biotinylation handles, and surface or biomolecule labeling reagents.

### Resources, FAQs, and evidence

#### [DBCO vs BCN](https://chemos.com/resources/dbco-vs-bcn)

How to compare two common copper-free click handles by reaction rate, steric profile, lipophilicity, and project fit.

- Question: When should DBCO be considered?
- Answer: Consider an exact DBCO derivative when its attachment chemistry, availability, solubility, reaction performance, purification, and analytical traceability fit the intended azide partner and matrix.
- Question: When should BCN be considered?
- Answer: Consider an exact BCN derivative when its compact aliphatic scaffold and available functionalization fit the construct, after checking reaction performance, thiol-rich conditions, stability, purification, and analysis.
- Evidence: [Visualizing Metabolically Labeled Glycoconjugates of Living Cells by Copper-Free and Fast Huisgen Cycloadditions](https://doi.org/10.1002/anie.200705456); [Readily Accessible Bicyclononynes for Bioorthogonal Labeling and Three-Dimensional Imaging of Living Cells](https://doi.org/10.1002/anie.201003761); [A Simple Method for Enhancing the Bioorthogonality of Cyclooctyne Reagent](https://pubs.rsc.org/en/content/articlelanding/2016/cc/c6cc01321j); [Evaluation of Dibenzocyclooctyne and Bicyclononyne Click Reaction on Azido-Functionalized Antifouling Polymer Brushes via Microspotting](https://doi.org/10.1002/admi.202102325)

#### [SPAAC vs IEDDA](https://chemos.com/resources/spaac-vs-iedda)

A practical comparison of azide-cyclooctyne SPAAC and tetrazine ligation for bioorthogonal conjugation.

- Question: What is the main selection factor?
- Answer: The main factor is whether one exact reaction pair provides the required conversion within the available time while both installed handles remain stable and compatible with the complete workflow.
- Question: Can both strategies be used in the same program?
- Answer: They can be compared or combined, but cross-reactivity, handle stability, installation order, purification, and analytical discrimination must be demonstrated in the actual system.
- Evidence: [A Strain-Promoted [3 + 2] Azide–Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems](https://pubs.acs.org/doi/10.1021/ja044996f); [Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels–Alder Reactivity](https://pubs.acs.org/doi/10.1021/ja8053805); [Uncovering the Key Role of Distortion in Bioorthogonal Tetrazine Tools That Defy the Reactivity/Stability Trade-Off](https://pubs.acs.org/doi/10.1021/jacs.2c01056); [Trans-Cyclooctene Isomerization Catalyzed by Thiamine Degradation Products in Cell Culture Media](https://pubs.acs.org/doi/10.1021/acsomega.5c01780)

#### [DOTA vs NOTA vs DFO](https://chemos.com/resources/dota-vs-nota-vs-dfo)

Compare three chelator families by intended metal, complexation conditions, vector tolerance, bifunctional derivative, and analytical plan.

- Question: Is one chelator universally best?
- Answer: No. The exact metal, derivative, complexation conditions, vector, attachment method, required lifetime, purification, and analytical evidence determine suitability.
- Question: Does CHEMOS supply radioactive materials?
- Answer: No. CHEMOS focuses on selected cold, non-radioactive chelators, bifunctional derivatives, intermediates, and precursor building blocks.
- Evidence: [Comparison of Macrocyclic and Acyclic Chelators for Gallium-68 Radiolabelling](https://doi.org/10.1039/C7RA09076E); [Side by Side Comparison of NOTA and DOTA for Conjugation Efficiency, Gallium-68 Labeling, and In Vivo Biodistribution of Anti-Mesothelin sdAb A1-His](https://doi.org/10.1186/s41181-025-00380-5); [A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89](https://doi.org/10.1021/acs.inorgchem.0c01629); [A First-in-Class Dual-Chelator Theranostic Agent Designed for Use with Imaging-Therapy Radiometal Pairs of Different Elements](https://doi.org/10.1039/D4SC02851A)

#### [Ionizable Lipid Design](https://chemos.com/resources/ionizable-lipid-design)

Define ionizable-lipid analogs through exact structure, formulation role, cargo, route, degradation hypothesis, and material controls.

- Question: What information helps scope a custom lipid analog?
- Answer: An exact structure or controlled analog series, intended formulation and cargo, quantity, material specification, analytical plan, study context, and customer-provided IP or FTO constraints are needed.
- Question: Does a named or reference lipid imply rights or equivalent performance?
- Answer: No. A name may identify a structural reference only. It does not imply third-party rights, freedom to operate, identical composition, or equivalent formulation and biological performance.
- Evidence: [Rational Design of Cationic Lipids for siRNA Delivery](https://doi.org/10.1038/nbt.1602); [Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics](https://doi.org/10.1038/mt.2013.124); [Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity](https://doi.org/10.1038/ncomms5277); [Ionization and Structural Properties of mRNA Lipid Nanoparticles Influence Expression in Intramuscular and Intravascular Administration](https://doi.org/10.1038/s42003-021-02441-2)

#### [PEG-Lipid Selection](https://chemos.com/resources/peg-lipid-selection)

Select PEG lipids by anchor, PEG definition, terminal group, formulation ratio, retention or desorption hypothesis, and analytical control.

- Question: What should be matched before ordering a PEG lipid?
- Answer: Match the exact anchor, linker, PEG definition, terminal group, material specification, formulation ratio, process, intended role, and analytical plan.
- Question: Can terminal functionality be customized?
- Answer: It can be evaluated when the complete structure, reactive-group content, quantity, stability constraints, formulation use, and analytical expectations are defined.
- Evidence: [Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles](https://doi.org/10.1038/mtna.2013.66); [Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method](https://doi.org/10.3390/pharmaceutics15020597); [Role of PEGylated Lipid in Lipid Nanoparticle Formulation for In Vitro and In Vivo Delivery of mRNA Vaccines](https://doi.org/10.1016/j.jconrel.2025.01.071); [The Impact of Polyethylene Glycol Lipid Anchors on the Physicochemical Properties, Protein Corona, Function, and Biodistribution of Lipid Nanoparticles](https://doi.org/10.1021/acsnano.5c19757)

#### [GalNAc vs Lipid Conjugation](https://chemos.com/resources/galnac-vs-lipid-conjugation)

Compare receptor-directed multivalent GalNAc and structure-dependent lipid conjugation as distinct oligonucleotide delivery strategies.

- Question: Can the same oligo use either route?
- Answer: A sequence can be used in separate GalNAc and lipid-conjugate studies, but the scaffold, linker, attachment, purification, dose, controls, and biological evaluation must be defined for each finished conjugate.
- Question: What product information matters first?
- Answer: Define the biological route, complete oligonucleotide modification map, exact ligand or lipid, attachment site, linker, conjugation method, specification, and study controls.
- Evidence: [siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes](https://doi.org/10.1021/cb501028c); [Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands](https://doi.org/10.1124/jpet.115.230300); [Hydrophobicity Drives the Systemic Distribution of Lipid-Conjugated siRNAs via Lipid Transport Pathways](https://doi.org/10.1093/nar/gky1232); [Diverse Lipid Conjugates for Functional Extra-Hepatic siRNA Delivery In Vivo](https://doi.org/10.1093/nar/gky1239)

#### [PROTAC Linker Selection](https://chemos.com/resources/protac-linker-selection)

Build linker series from both ligands, exit vectors, ternary-complex geometry, conformation, permeability, synthesis, and assay evidence.

- Question: Is linker length enough to define a PROTAC linker?
- Answer: No. Both ligands, exit vectors, composition, rigidity, polarity, conformation, permeability, stability, ternary-complex behavior, synthesis, and assays must be considered.
- Question: Can pre-functionalized ligand-linkers reduce iteration time?
- Answer: They can simplify synthesis when ligand, stereochemistry, exit vector, terminal handle, direction, and coupling plan match; they do not remove linker-series and biological testing.
- Evidence: [Structural Basis of PROTAC Cooperative Recognition for Selective Protein Degradation](https://doi.org/10.1038/nchembio.2329); [Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation](https://doi.org/10.1021/acsmedchemlett.2c00124); [Linker-Dependent Folding Rationalizes PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.2c00877); [Impact of Linker Composition on VHL PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.4c02492)

#### [Cleavable vs Non-cleavable ADC Linkers](https://chemos.com/resources/cleavable-vs-non-cleavable-linkers)

Compare ADC linker strategies by released species, trigger, circulation stability, intracellular processing, payload properties, conjugation format, and analytical evidence.

- Question: Is a cleavable linker always preferred?
- Answer: No. Cleavable and non-cleavable designs can both be appropriate. Selection requires the exact released species, target-cell processing, payload properties, conjugation format, stability window, and comparison data.
- Question: What is needed to scope a custom ADC linker?
- Answer: Provide the antibody and attachment site, payload structure and attachment atom, release or catabolite hypothesis, spacer and handle, target loading, stability conditions, analytical methods, and biological controls.
- Evidence: [Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing](https://doi.org/10.1158/0008-5472.CAN-05-4489); [The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates](https://doi.org/10.1158/1535-7163.MCT-11-0727); [Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate](https://doi.org/10.1158/1078-0432.CCR-04-0789); [Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates](https://doi.org/10.1021/bc5005747)

### Public-claim boundaries

- Product specifications, documentation, availability, and project scope are batch-specific or project-specific and should be confirmed directly with CHEMOS. Do not infer medical, therapeutic, inventory, pricing, or guaranteed delivery claims from this site.
- Products are specialty building blocks and chemical materials for research, development, further synthesis, or other uses agreed in writing. They are not offered for direct human or animal administration.

---

## 中文 (zh-CN)

> 面向寡核苷酸、多肽、ADC、PROTAC、放射性药物前体和递送应用的特色分子砌块与可放大偶联化学。

### 主要页面

- [首页](https://chemos.com/zh)
- [关于 CHEMOS](https://chemos.com/zh/about)
- [产品目录](https://chemos.com/zh/products)
- [技术平台](https://chemos.com/zh/technology-platforms)
- [工艺化学](https://chemos.com/zh/process-chemistry)
- [应用方向](https://chemos.com/zh/applications)
- [技术资源](https://chemos.com/zh/resources)
- [项目支持](https://chemos.com/zh/project-support)
- [联系我们](https://chemos.com/zh/contact)
- [提交询价](https://chemos.com/zh/rfq)

### 产品系列

- [寡核苷酸合成与修饰](https://chemos.com/zh/products/category/113-oligonucleotide-synthesis-rna-raw-materials-modification): 亚磷酰胺、修饰核苷、固相载体、硫化试剂、帽类似物及相关合成工具。
- [寡核苷酸偶联与递送配体](https://chemos.com/zh/products/category/114-oligonucleotide-conjugation-delivery-ligands): GalNAc 配体、脂质偶联基团、胆固醇衍生物、点击反应基团和寡核苷酸偶联连接子。
- [多肽合成与修饰](https://chemos.com/zh/products/category/115-peptide-synthesis-peptide-drug-modification): 当前目录列出部分糖肽相关砌块；其他多肽修饰目标需按结构、数量和规格评估。
- [点击化学与生物偶联](https://chemos.com/zh/products/category/116-click-chemistry-bioconjugation-reagents): DBCO、BCN、叠氮、TCO、四嗪、NHS 酯、马来酰亚胺及温和偶联用功能手柄。
- [ADC 连接子与偶联试剂](https://chemos.com/zh/products/category/117-adc-linkers-conjugation-reagents): 可裂解和稳定连接子、亲水间隔基、反应基团以及载荷-连接子中间体支持。
- [ADC 载荷与高活性中间体](https://chemos.com/zh/products/category/118-adc-payloads-hpapi-intermediates): 针对项目的载荷和高活性中间体需求，按准确结构、数量、操作限制、规格及分析要求进行评估。
- [PROTAC、E3 配体与邻近诱导砌块](https://chemos.com/zh/products/category/119-protac-e3-ligands-proximity-inducing-building-blocks): E3 连接酶配体衍生物、功能化 linker、双功能中间体及用于 PROTAC 与邻近诱导研究的其他砌块。
- [放射性药物螯合剂与前体](https://chemos.com/zh/products/category/120-radiopharmaceutical-chelators-precursors-targeting-ligands): DOTA、NOTA、DFO、DTPA、双功能螯合剂，以及成像和放射性配体项目用非放射性前体砌块。
- [LNP 与递送脂质](https://chemos.com/zh/products/category/121-lnp-nucleic-acid-delivery-lipids): 可电离脂质类似物、PEG 脂质、辅助磷脂、胆固醇衍生物和功能化递送脂质工具。
- [荧光标记、生物素化与探针](https://chemos.com/zh/products/category/122-fluorescent-labeling-biotinylation-probes): 用于标记和检测研究的荧光及显色探针、生物素化砌块、染料前体和功能化反应基团。

### 技术平台

- [偶联化学与 连接子](https://chemos.com/zh/technology-platforms/conjugation-chemistry-linkers): 用于连接寡核苷酸、多肽、蛋白、载荷、螯合剂和脂质材料的 连接子 设计与功能手柄。
- [点击化学与生物正交化学](https://chemos.com/zh/technology-platforms/click-bioorthogonal-chemistry): 无铜点击、四嗪连接、CuAAC 兼容手柄，以及敏感生物分子流程中的标记化学。
- [寡核苷酸修饰](https://chemos.com/zh/technology-platforms/oligonucleotide-modification): 用于 ASO、siRNA、guide RNA、适配体以及研究或标记项目的糖、碱基、骨架、末端和偶联修饰。
- [多肽修饰与糖肽](https://chemos.com/zh/technology-platforms/peptide-modification): 非天然氨基酸、脂肪酸化、PEG 化、糖基化残基、订书肽工具和多肽偶联化学。
- [ADC 连接子-载荷 化学](https://chemos.com/zh/technology-platforms/adc-linker-payload): 可裂解 连接子、稳定 连接子、亲水 间隔基、位点选择性手柄和 载荷-连接子 中间体化学。
- [PROTAC / TPD 砌块](https://chemos.com/zh/technology-platforms/protac-tpd-building-blocks): CRBN 和 VHL 配体衍生物、配体-连接子、双功能降解剂中间体和 连接子 调节砌块。
- [放射性药物螯合剂](https://chemos.com/zh/technology-platforms/radiopharmaceutical-chelators): 大环和开链螯合剂、双功能手柄，以及非放射性前体砌块。
- [递送用脂质材料](https://chemos.com/zh/technology-platforms/lipid-materials-delivery): 可电离脂质类似物、PEG 脂质、磷脂、甾醇和配体-脂质偶联物，用于递送研究。

### 工艺化学

- [氟化化学](https://chemos.com/zh/process-chemistry/fluorination): 支持含氟砌块、氟烷基片段和含氟杂环的路线评估与制备。
- [磷化学](https://chemos.com/zh/process-chemistry/phosphorus-chemistry): 亚磷酰胺、膦酸酯衍生物、磷酸化试剂和相关含磷中间体。
- [硫化学](https://chemos.com/zh/process-chemistry/sulfur-chemistry): 硫化试剂、硫醚、磺酰化合物、二硫化物和含硫 连接子 化学。
- [手性化学](https://chemos.com/zh/process-chemistry/chiral): 手性砌块、拆分策略、不对称路线支持和立体化学分析控制。
- [流动化学](https://chemos.com/zh/process-chemistry/flow): 为受益于传热、混合或停留时间控制的反应提供工艺强化支持。
- [寡核苷酸合成](https://chemos.com/zh/process-chemistry/oligonucleotide-synthesis): 支持修饰单体、固相载体、硫化试剂、帽类似物和相关寡核苷酸合成输入物。
- [PEG 化与 PEG 连接子 合成](https://chemos.com/zh/process-chemistry/pegylation): PEG 间隔基、PEG 脂质材料、PEG 连接子、异双功能 PEG 手柄和纯化规划。
- [放大支持](https://chemos.com/zh/process-chemistry/scale-up-support): 为选定特色砌块和偶联试剂提供项目批次放大支持。
- [分析方法支持](https://chemos.com/zh/process-chemistry/analytical-method-support): 围绕身份、纯度、杂质谱和批次技术文件提供方法支持。
- [杂质谱研究](https://chemos.com/zh/process-chemistry/impurity-profiling): 用于路线开发、纯化决策和项目批次可比性的杂质跟踪。

### 应用方向

- [寡核苷酸项目](https://chemos.com/zh/applications/oligonucleotide-therapeutics): 用于 ASO、siRNA、guide RNA、适配体以及研究或标记寡核苷酸项目的砌块和修饰化学。
- [siRNA 研究项目](https://chemos.com/zh/applications/sirna-therapeutics): 用于 siRNA 研究流程的修饰单体、GalNAc 配体、脂质偶联手柄和硫化试剂。
- [mRNA 与 LNP 材料](https://chemos.com/zh/applications/mrna-therapeutics): 帽类似物、修饰 NTP、可电离脂质类似物、PEG 脂质、辅助脂质和脂质材料研究工具。
- [靶向 LNP 递送材料](https://chemos.com/zh/applications/targeted-lnp): 靶向配体、配体-脂质偶联物、PEG 脂质变体、可电离脂质类似物和辅助脂质材料。
- [肝细胞靶向递送](https://chemos.com/zh/applications/hepatocyte-targeted-delivery): GalNAc 配体、寡核苷酸偶联手柄、脂质偶联物和肝靶向递送研究中的 连接子 选择。
- [肝外递送](https://chemos.com/zh/applications/extrahepatic-delivery): 用于肝外递送项目的替代递送配体、脂质材料和偶联手柄。
- [ADC 开发相关化学](https://chemos.com/zh/applications/adc-development): 连接子、间隔基、位点选择性手柄、类螯合连接片段和 载荷-连接子 中间体支持。
- [PROTAC 发现](https://chemos.com/zh/applications/protac-discovery): E3 配体、配体-连接子、PEG 和烷基 连接子、点击手柄以及双功能降解剂中间体支持。
- [放射性药物相关前体](https://chemos.com/zh/applications/radiopharmaceuticals): 冷态螯合剂、双功能手柄、PSMA/FAPI 前体砌块和非放射性放射性配体输入物。
- [标记与成像](https://chemos.com/zh/applications/labeling): 生物正交手柄、染料连接工具、生物素化手柄，以及表面或生物分子标记试剂。

### 技术资源、常见问题与依据

#### [DBCO 与 BCN 对比](https://chemos.com/zh/resources/dbco-vs-bcn)

从反应速率、空间构型、亲脂性和项目适配角度比较两类常见无铜点击手柄。

- 问题: 什么时候考虑 DBCO？
- 回答: 当具体 DBCO 衍生物的连接化学、可得性、溶解性、反应表现、纯化和分析可追踪性适合预定叠氮伙伴与基质时考虑。
- 问题: 什么时候考虑 BCN？
- 回答: 当具体 BCN 衍生物的紧凑脂肪族骨架和功能化形式适合构建体，并已检查反应表现、富硫醇条件、稳定性、纯化和分析时考虑。
- 参考依据: [Visualizing Metabolically Labeled Glycoconjugates of Living Cells by Copper-Free and Fast Huisgen Cycloadditions](https://doi.org/10.1002/anie.200705456); [Readily Accessible Bicyclononynes for Bioorthogonal Labeling and Three-Dimensional Imaging of Living Cells](https://doi.org/10.1002/anie.201003761); [A Simple Method for Enhancing the Bioorthogonality of Cyclooctyne Reagent](https://pubs.rsc.org/en/content/articlelanding/2016/cc/c6cc01321j); [Evaluation of Dibenzocyclooctyne and Bicyclononyne Click Reaction on Azido-Functionalized Antifouling Polymer Brushes via Microspotting](https://doi.org/10.1002/admi.202102325)

#### [SPAAC 与 IEDDA 对比](https://chemos.com/zh/resources/spaac-vs-iedda)

面向生物正交偶联的叠氮-环辛炔 SPAAC 与四嗪连接实用对比。

- 问题: 主要选择因素是什么？
- 回答: 准确反应对能否在可用时间内达到所需转化，同时两个已安装手柄在完整流程中保持稳定和相容。
- 问题: 同一项目能比较或组合两种策略吗？
- 回答: 可以，但必须在实际体系中证明交叉反应、稳定性、安装顺序、纯化和分析区分。
- 参考依据: [A Strain-Promoted [3 + 2] Azide–Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems](https://pubs.acs.org/doi/10.1021/ja044996f); [Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels–Alder Reactivity](https://pubs.acs.org/doi/10.1021/ja8053805); [Uncovering the Key Role of Distortion in Bioorthogonal Tetrazine Tools That Defy the Reactivity/Stability Trade-Off](https://pubs.acs.org/doi/10.1021/jacs.2c01056); [Trans-Cyclooctene Isomerization Catalyzed by Thiamine Degradation Products in Cell Culture Media](https://pubs.acs.org/doi/10.1021/acsomega.5c01780)

#### [DOTA、NOTA 与 DFO 对比](https://chemos.com/zh/resources/dota-vs-nota-vs-dfo)

按目标金属、配位条件、载体耐受性、双功能衍生物和分析方案比较三类螯合剂。

- 问题: 是否存在通用最佳螯合剂？
- 回答: 不存在。准确金属、衍生物、配位条件、载体、连接方式、所需寿命、纯化和分析证据共同决定适用性。
- 问题: CHEMOS 是否供应放射性材料？
- 回答: 不供应。CHEMOS 聚焦选定的冷态、非放射性螯合剂、双功能衍生物、中间体和前体砌块。
- 参考依据: [Comparison of Macrocyclic and Acyclic Chelators for Gallium-68 Radiolabelling](https://doi.org/10.1039/C7RA09076E); [Side by Side Comparison of NOTA and DOTA for Conjugation Efficiency, Gallium-68 Labeling, and In Vivo Biodistribution of Anti-Mesothelin sdAb A1-His](https://doi.org/10.1186/s41181-025-00380-5); [A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89](https://doi.org/10.1021/acs.inorgchem.0c01629); [A First-in-Class Dual-Chelator Theranostic Agent Designed for Use with Imaging-Therapy Radiometal Pairs of Different Elements](https://doi.org/10.1039/D4SC02851A)

#### [可电离脂质设计](https://chemos.com/zh/resources/ionizable-lipid-design)

按准确结构、配方角色、载荷、给药或实验方式、降解假设和物料控制定义可电离脂质类似物。

- 问题: 哪些信息有助于确认定制脂质类似物？
- 回答: 需要准确结构或受控类似物系列、预定配方和载荷、数量、物料规格、分析方案、研究背景，以及客户提供的 IP 或 FTO 限制。
- 问题: 命名或参考脂质是否意味着权利或等效性能？
- 回答: 不意味着。名称只可作为结构参考，不代表第三方权利、自由实施、相同组成或等效配方与生物表现。
- 参考依据: [Rational Design of Cationic Lipids for siRNA Delivery](https://doi.org/10.1038/nbt.1602); [Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics](https://doi.org/10.1038/mt.2013.124); [Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity](https://doi.org/10.1038/ncomms5277); [Ionization and Structural Properties of mRNA Lipid Nanoparticles Influence Expression in Intramuscular and Intravascular Administration](https://doi.org/10.1038/s42003-021-02441-2)

#### [PEG 脂质选择](https://chemos.com/zh/resources/peg-lipid-selection)

按锚定基、PEG 定义、末端基、配方比例、保留或脱附假设和分析控制选择 PEG 脂质。

- 问题: 订购 PEG 脂质前应先匹配什么？
- 回答: 应匹配准确锚定基、连接子、PEG 定义、末端基、物料规格、配方比例、工艺、预定角色和分析方案。
- 问题: 末端功能可以定制吗？
- 回答: 当完整结构、反应基含量、数量、稳定性限制、配方用途和分析要求明确时可以评估。
- 参考依据: [Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles](https://doi.org/10.1038/mtna.2013.66); [Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method](https://doi.org/10.3390/pharmaceutics15020597); [Role of PEGylated Lipid in Lipid Nanoparticle Formulation for In Vitro and In Vivo Delivery of mRNA Vaccines](https://doi.org/10.1016/j.jconrel.2025.01.071); [The Impact of Polyethylene Glycol Lipid Anchors on the Physicochemical Properties, Protein Corona, Function, and Biodistribution of Lipid Nanoparticles](https://doi.org/10.1021/acsnano.5c19757)

#### [GalNAc 与脂质偶联对比](https://chemos.com/zh/resources/galnac-vs-lipid-conjugation)

比较受体导向的多价 GalNAc 与结构依赖的脂质偶联这两类不同的寡核苷酸递送策略。

- 问题: 同一寡核苷酸能使用两种路线吗？
- 回答: 同一序列可分别开展两类研究，但每个成品的骨架、连接子、位点、纯化、剂量、对照和生物评价需独立定义。
- 问题: 最先需要明确哪些产品信息？
- 回答: 先定义生物通路、完整修饰图、准确配体或脂质、连接位点、连接子、偶联方法、规格和研究对照。
- 参考依据: [siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes](https://doi.org/10.1021/cb501028c); [Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands](https://doi.org/10.1124/jpet.115.230300); [Hydrophobicity Drives the Systemic Distribution of Lipid-Conjugated siRNAs via Lipid Transport Pathways](https://doi.org/10.1093/nar/gky1232); [Diverse Lipid Conjugates for Functional Extra-Hepatic siRNA Delivery In Vivo](https://doi.org/10.1093/nar/gky1239)

#### [PROTAC 连接子 选择](https://chemos.com/zh/resources/protac-linker-selection)

根据两端配体、exit vector、三元复合物几何、构象、通透性、合成和实验数据设计 连接子 系列。

- 问题: 只看 连接子 长度就够了吗？
- 回答: 不够。两端配体、exit vector、组成、刚性、极性、构象、通透性、稳定性、三元复合物、合成和实验结果都需考虑。
- 问题: 预功能化配体-连接子 能减少迭代时间吗？
- 回答: 当配体、立体化学、exit vector、末端手柄、方向和偶联方案匹配时可简化合成，但不能替代 连接子 系列与生物测试。
- 参考依据: [Structural Basis of PROTAC Cooperative Recognition for Selective Protein Degradation](https://doi.org/10.1038/nchembio.2329); [Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation](https://doi.org/10.1021/acsmedchemlett.2c00124); [Linker-Dependent Folding Rationalizes PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.2c00877); [Impact of Linker Composition on VHL PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.4c02492)

#### [可裂解与不可裂解 ADC 连接子](https://chemos.com/zh/resources/cleavable-vs-non-cleavable-linkers)

根据实际释放物、触发机制、循环稳定性、细胞内处理、载荷 性质、偶联形式和分析证据比较 ADC 连接子。

- 问题: 可裂解 连接子 总是更优吗？
- 回答: 不是。两类设计都可能适用，必须结合实际释放物、靶细胞处理、载荷 性质、偶联形式、稳定窗口和对比数据选择。
- 问题: 确认定制 ADC 连接子 需要什么信息？
- 回答: 应提供抗体与连接位点、载荷 结构与连接原子、释放或分解产物假设、间隔基 与手柄、目标 DAR、稳定条件、分析方法和生物对照。
- 参考依据: [Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing](https://doi.org/10.1158/0008-5472.CAN-05-4489); [The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates](https://doi.org/10.1158/1535-7163.MCT-11-0727); [Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate](https://doi.org/10.1158/1078-0432.CCR-04-0789); [Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates](https://doi.org/10.1021/bc5005747)

### 公开声明边界

- 产品规格、技术文件、可供性和项目范围均以具体批次或具体项目确认为准，请直接与 CHEMOS 沟通确认。请勿从本站内容推断医疗、治疗、库存、价格或保证交付承诺。
- 产品为用于研究、开发、进一步合成或书面约定其他用途的特种化学砌块及化学材料，不面向人体或动物直接给药。

---

## Español (es)

> Bloques de síntesis especializados y química de conjugación escalable para aplicaciones de oligonucleótidos, péptidos, ADC, PROTAC, radiofármacos y sistemas de administración.

### Páginas principales

- [Inicio](https://chemos.com/es)
- [Acerca de CHEMOS](https://chemos.com/es/about)
- [Productos](https://chemos.com/es/products)
- [Plataformas tecnológicas](https://chemos.com/es/technology-platforms)
- [Química de procesos](https://chemos.com/es/process-chemistry)
- [Aplicaciones](https://chemos.com/es/applications)
- [Recursos](https://chemos.com/es/resources)
- [Soporte de proyectos](https://chemos.com/es/project-support)
- [Contacto](https://chemos.com/es/contact)
- [Solicitud de cotización](https://chemos.com/es/rfq)

### Familias de productos

- [Síntesis y modificación de oligonucleótidos](https://chemos.com/es/products/category/113-oligonucleotide-synthesis-rna-raw-materials-modification): Fosforamiditas, nucleósidos modificados, soportes sólidos, reactivos de sulfuración, análogos de caperuza y herramientas relacionadas.
- [Conjugación de oligos y ligandos de administración](https://chemos.com/es/products/category/114-oligonucleotide-conjugation-delivery-ligands): Ligandos GalNAc, grupos para conjugación lipídica, derivados de colesterol, grupos para química click y enlazadores para oligos.
- [Síntesis y modificación de péptidos](https://chemos.com/es/products/category/115-peptide-synthesis-peptide-drug-modification): El catálogo actual incluye algunos bloques relacionados con glicopéptidos; otros objetivos de modificación se evalúan según estructura, cantidad y especificación.
- [Química click y bioconjugación](https://chemos.com/es/products/category/116-click-chemistry-bioconjugation-reagents): DBCO, BCN, azidas, TCO, tetrazinas, ésteres NHS, maleimidas y otros grupos para conjugación en condiciones suaves.
- [Enlazadores ADC y reactivos de conjugación](https://chemos.com/es/products/category/117-adc-linkers-conjugation-reagents): Enlazadores escindibles y estables, espaciadores hidrofílicos, grupos reactivos y soporte para intermedios de carga-enlazador.
- [Cargas ADC e intermedios HPAPI](https://chemos.com/es/products/category/118-adc-payloads-hpapi-intermediates): Solicitudes de cargas e intermedios de alta potencia evaluadas por estructura exacta, cantidad, restricciones de manipulación, especificación y requisitos analíticos.
- [PROTAC, ligandos E3 y bloques de proximidad inducida](https://chemos.com/es/products/category/119-protac-e3-ligands-proximity-inducing-building-blocks): Derivados de ligandos E3, enlazadores funcionalizados, intermedios bifuncionales y otros bloques para investigación PROTAC y de proximidad inducida.
- [Quelantes y precursores radiofarmacéuticos](https://chemos.com/es/products/category/120-radiopharmaceutical-chelators-precursors-targeting-ligands): DOTA, NOTA, DFO, DTPA, quelantes bifuncionales y precursores fríos para imagen y programas de radioligandos.
- [LNP y lípidos de administración](https://chemos.com/es/products/category/121-lnp-nucleic-acid-delivery-lipids): Análogos de lípidos ionizables, lípidos PEG, fosfolípidos auxiliares, derivados de colesterol y lípidos funcionales para sistemas de administración.
- [Marcaje fluorescente, biotinilación y sondas](https://chemos.com/es/products/category/122-fluorescent-labeling-biotinylation-probes): Sondas fluorescentes y cromogénicas, bloques para biotinilación, precursores de colorantes y grupos funcionales para investigación de marcaje y detección.

### Plataformas tecnológicas

- [Química de conjugación y enlazadores](https://chemos.com/es/technology-platforms/conjugation-chemistry-linkers): Diseño de enlazadores y grupos funcionales para unir oligos, péptidos, proteínas, cargas, quelantes y lípidos.
- [Click y química bioortogonal](https://chemos.com/es/technology-platforms/click-bioorthogonal-chemistry): Click sin cobre, ligación con tetrazina, grupos CuAAC y química de marcaje.
- [Modificación de oligonucleótidos](https://chemos.com/es/technology-platforms/oligonucleotide-modification): Modificaciones de azúcar, base, backbone, terminal y conjugación para ASO, siRNA, guide RNA, aptámeros y oligos.
- [Modificación de péptidos y glicopéptidos](https://chemos.com/es/technology-platforms/peptide-modification): Aminoácidos no naturales, lipidación, PEGilación, residuos glicosilados, grapado y conjugación.
- [Química de enlazadores y cargas para ADC](https://chemos.com/es/technology-platforms/adc-linker-payload): Enlazadores escindibles o estables, espaciadores hidrofílicos, grupos reactivos selectivos e intermedios carga-enlazador.
- [Bloques de síntesis PROTAC / TPD](https://chemos.com/es/technology-platforms/protac-tpd-building-blocks): Derivados CRBN/VHL, ligando-enlazadores, intermedios bifuncionales y bloques de síntesis de enlazador.
- [Quelantes radiofarmacéuticos](https://chemos.com/es/technology-platforms/radiopharmaceutical-chelators): Quelantes macrocíclicos y acíclicos, grupos bifuncionales y precursores no radiactivos.
- [Materiales lipídicos para administración](https://chemos.com/es/technology-platforms/lipid-materials-delivery): Análogos de lípidos ionizables, PEG-lípidos, fosfolípidos, esteroles y conjugados ligando-lípido para investigación.

### Química de procesos

- [Química de fluoración](https://chemos.com/es/process-chemistry/fluorination): Soporte de ruta para bloques de síntesis fluorados, motivos fluoroalquilo y heterociclos fluorados.
- [Química de fósforo](https://chemos.com/es/process-chemistry/phosphorus-chemistry): Fosforamiditas, derivados fosfonato, reactivos de fosforilación e intermedios con fósforo.
- [Química de azufre](https://chemos.com/es/process-chemistry/sulfur-chemistry): Reactivos de sulfuración, tioéteres, compuestos sulfonilo, disulfuros y enlazadores con azufre.
- [Química quiral](https://chemos.com/es/process-chemistry/chiral): Bloques de síntesis quirales, estrategias de resolución, rutas asimétricas y control estereoquímico.
- [Química de flujo](https://chemos.com/es/process-chemistry/flow): Soporte de intensificación para reacciones que se benefician de transferencia de calor, mezcla o tiempo de residencia controlados.
- [Síntesis de oligonucleótidos](https://chemos.com/es/process-chemistry/oligonucleotide-synthesis): Soporte para monómeros modificados, soportes, reactivos de sulfuración, análogos de caperuza e insumos relacionados.
- [PEGilación y síntesis de enlazadores PEG](https://chemos.com/es/process-chemistry/pegylation): espaciadores PEG, materiales lípido PEG, enlazadores PEG, grupos reactivos PEG heterobifuncionales y planificación de purificación.
- [Soporte de escalado](https://chemos.com/es/process-chemistry/scale-up-support): Soporte de escalado de lotes de proyecto para bloques de síntesis y reactivos de conjugación seleccionados.
- [Soporte de método analítico](https://chemos.com/es/process-chemistry/analytical-method-support): Soporte para identidad, pureza, perfil de impurezas y documentación técnica por lote.
- [Perfil de impurezas](https://chemos.com/es/process-chemistry/impurity-profiling): Seguimiento de impurezas para desarrollo de ruta, decisiones de purificación y comparabilidad de lotes.

### Aplicaciones

- [Programas de oligonucleótidos](https://chemos.com/es/applications/oligonucleotide-therapeutics): Bloques de síntesis y química de modificación para ASO, siRNA, guide RNA, aptámeros y oligos de investigación o marcaje.
- [Programas de investigación siRNA](https://chemos.com/es/applications/sirna-therapeutics): Monómeros modificados, ligandos GalNAc, grupos reactivos de conjugación lipídica y reactivos de sulfuración para flujo de trabajos siRNA.
- [Materiales mRNA y LNP](https://chemos.com/es/applications/mrna-therapeutics): Análogos de caperuza, NTPs modificados, análogos de lípidos ionizables, PEG-lípidos, lípidos auxiliares y herramientas lipídicas.
- [Materiales para LNP dirigidas](https://chemos.com/es/applications/targeted-lnp): Ligandos de direccionamiento, conjugados ligando-lípido, variantes de lípidos PEG, análogos de lípidos ionizables y lípidos auxiliares.
- [administración dirigida a hepatocitos](https://chemos.com/es/applications/hepatocyte-targeted-delivery): ligandos GalNAc, grupos reactivos de conjugación de oligos, conjugados lipídicos y enlazadores para administración dirigida al hígado.
- [administración extrahepática](https://chemos.com/es/applications/extrahepatic-delivery): ligandos alternativos, materiales lipídicos y grupos reactivos de conjugación para administración fuera de programas hepáticos.
- [Desarrollo relacionado con ADC](https://chemos.com/es/applications/adc-development): Enlazadores, espaciadores, grupos reactivos selectivos por sitio, motivos de unión tipo quelante y soporte para intermedios carga-enlazador.
- [Descubrimiento PROTAC](https://chemos.com/es/applications/protac-discovery): ligandos E3, intermedios ligando-enlazador, enlazadores PEG y alquilo, grupos click e intermedios bifuncionales.
- [Precursores radiofarmacéuticos](https://chemos.com/es/applications/radiopharmaceuticals): Quelantes fríos, grupos bifuncionales, intermedios PSMA/FAPI y bloques de síntesis no radiactivos.
- [Marcaje e imagen](https://chemos.com/es/applications/labeling): Grupos bioortogonales, herramientas para dyes, biotinilación y reactivos de marcaje de superficies o biomoléculas.

### Recursos, preguntas frecuentes y fuentes

#### [DBCO vs BCN](https://chemos.com/es/resources/dbco-vs-bcn)

Comparación de dos grupos reactivos click sin cobre por velocidad, perfil estérico, lipofilicidad y ajuste de proyecto.

- Pregunta: ¿Cuándo considerar DBCO?
- Respuesta: Cuando el derivado exacto encaja en química, solubilidad, reacción, purificación y análisis del sistema previsto.
- Pregunta: ¿Cuándo considerar BCN?
- Respuesta: Cuando su armazón y derivado encajan tras comprobar reacción, tioles, estabilidad, purificación y análisis.
- Fuentes: [Visualizing Metabolically Labeled Glycoconjugates of Living Cells by Copper-Free and Fast Huisgen Cycloadditions](https://doi.org/10.1002/anie.200705456); [Readily Accessible Bicyclononynes for Bioorthogonal Labeling and Three-Dimensional Imaging of Living Cells](https://doi.org/10.1002/anie.201003761); [A Simple Method for Enhancing the Bioorthogonality of Cyclooctyne Reagent](https://pubs.rsc.org/en/content/articlelanding/2016/cc/c6cc01321j); [Evaluation of Dibenzocyclooctyne and Bicyclononyne Click Reaction on Azido-Functionalized Antifouling Polymer Brushes via Microspotting](https://doi.org/10.1002/admi.202102325)

#### [SPAAC vs IEDDA](https://chemos.com/es/resources/spaac-vs-iedda)

Comparación práctica de SPAAC azida-ciclooctino e IEDDA tetrazina-dienófilo tensionado para conjugación bioortogonal.

- Pregunta: ¿Cuál es el factor principal?
- Respuesta: Que el par exacto alcance la conversión necesaria en el tiempo disponible y que ambos grupos reactivos instalados permanezcan estables y compatibles durante todo el proceso.
- Pregunta: ¿Pueden compararse o combinarse ambas estrategias?
- Respuesta: Sí, pero deben demostrarse reactividad cruzada, estabilidad, orden de instalación, purificación y diferenciación analítica en el sistema real.
- Fuentes: [A Strain-Promoted [3 + 2] Azide–Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems](https://pubs.acs.org/doi/10.1021/ja044996f); [Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels–Alder Reactivity](https://pubs.acs.org/doi/10.1021/ja8053805); [Uncovering the Key Role of Distortion in Bioorthogonal Tetrazine Tools That Defy the Reactivity/Stability Trade-Off](https://pubs.acs.org/doi/10.1021/jacs.2c01056); [Trans-Cyclooctene Isomerization Catalyzed by Thiamine Degradation Products in Cell Culture Media](https://pubs.acs.org/doi/10.1021/acsomega.5c01780)

#### [DOTA vs NOTA vs DFO](https://chemos.com/es/resources/dota-vs-nota-vs-dfo)

Comparar tres familias por metal previsto, condiciones de complejación, tolerancia del vector, derivado bifuncional y plan analítico.

- Pregunta: ¿Hay un quelante universal?
- Respuesta: No. Metal, derivado, condiciones, vector, unión, vida requerida, purificación y evidencia analítica determinan la idoneidad.
- Pregunta: ¿CHEMOS suministra materiales radiactivos?
- Respuesta: No. CHEMOS se centra en quelantes fríos no radiactivos seleccionados, derivados bifuncionales, intermedios y precursores.
- Fuentes: [Comparison of Macrocyclic and Acyclic Chelators for Gallium-68 Radiolabelling](https://doi.org/10.1039/C7RA09076E); [Side by Side Comparison of NOTA and DOTA for Conjugation Efficiency, Gallium-68 Labeling, and In Vivo Biodistribution of Anti-Mesothelin sdAb A1-His](https://doi.org/10.1186/s41181-025-00380-5); [A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89](https://doi.org/10.1021/acs.inorgchem.0c01629); [A First-in-Class Dual-Chelator Theranostic Agent Designed for Use with Imaging-Therapy Radiometal Pairs of Different Elements](https://doi.org/10.1039/D4SC02851A)

#### [Diseño de lípidos ionizables](https://chemos.com/es/resources/ionizable-lipid-design)

Definir análogos por estructura exacta, rol en formulación, cargo, vía experimental, hipótesis de degradación y controles de material.

- Pregunta: ¿Qué ayuda a definir un lípido a medida?
- Respuesta: Estructura exacta o serie controlada, formulación y cargo, cantidad, especificación, análisis, contexto del estudio y restricciones IP/FTO del cliente.
- Pregunta: ¿Un lípido nombrado implica derechos o desempeño equivalente?
- Respuesta: No. Solo puede ser referencia estructural; no implica derechos, FTO, composición ni desempeño equivalente.
- Fuentes: [Rational Design of Cationic Lipids for siRNA Delivery](https://doi.org/10.1038/nbt.1602); [Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics](https://doi.org/10.1038/mt.2013.124); [Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity](https://doi.org/10.1038/ncomms5277); [Ionization and Structural Properties of mRNA Lipid Nanoparticles Influence Expression in Intramuscular and Intravascular Administration](https://doi.org/10.1038/s42003-021-02441-2)

#### [Selección de PEG-lípidos](https://chemos.com/es/resources/peg-lipid-selection)

Seleccionar por ancla, definición de PEG, terminal, proporción, hipótesis de retención o desorción y control analítico.

- Pregunta: ¿Qué debe coincidir antes de pedir?
- Respuesta: Ancla, enlazador, definición PEG, terminal, especificación, proporción, proceso, función y análisis.
- Pregunta: ¿Puede personalizarse la funcionalidad terminal?
- Respuesta: Puede evaluarse con estructura, contenido reactivo, cantidad, estabilidad, uso y análisis definidos.
- Fuentes: [Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles](https://doi.org/10.1038/mtna.2013.66); [Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method](https://doi.org/10.3390/pharmaceutics15020597); [Role of PEGylated Lipid in Lipid Nanoparticle Formulation for In Vitro and In Vivo Delivery of mRNA Vaccines](https://doi.org/10.1016/j.jconrel.2025.01.071); [The Impact of Polyethylene Glycol Lipid Anchors on the Physicochemical Properties, Protein Corona, Function, and Biodistribution of Lipid Nanoparticles](https://doi.org/10.1021/acsnano.5c19757)

#### [GalNAc vs conjugación lipídica](https://chemos.com/es/resources/galnac-vs-lipid-conjugation)

Comparar GalNAc multivalente dirigido a receptor y conjugación lipídica dependiente de estructura como estrategias distintas.

- Pregunta: ¿Puede el mismo oligo usar ambas rutas?
- Respuesta: Puede estudiarse en ambas, pero armazón, enlazador, sitio, purificación, dosis, controles y evaluación se definen para cada conjugado.
- Pregunta: ¿Qué información importa primero?
- Respuesta: Ruta biológica, mapa del oligo, ligando exacto, sitio, enlazador, método, especificación y controles.
- Fuentes: [siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes](https://doi.org/10.1021/cb501028c); [Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands](https://doi.org/10.1124/jpet.115.230300); [Hydrophobicity Drives the Systemic Distribution of Lipid-Conjugated siRNAs via Lipid Transport Pathways](https://doi.org/10.1093/nar/gky1232); [Diverse Lipid Conjugates for Functional Extra-Hepatic siRNA Delivery In Vivo](https://doi.org/10.1093/nar/gky1239)

#### [Selección de enlazador PROTAC](https://chemos.com/es/resources/protac-linker-selection)

Diseñar series desde ambos ligandos, vectores de salida, geometría ternaria, conformación, permeabilidad, síntesis y ensayos.

- Pregunta: ¿Basta la longitud del enlazador?
- Respuesta: No. ligandos, vectores de salida, composición, conformación, permeabilidad, estabilidad, complejo, síntesis y ensayos importan.
- Pregunta: ¿Los ligando-enlazadores reducen iteración?
- Respuesta: Simplifican síntesis si ligando, estereoquímica, vector de salida, grupo reactivo, dirección y acoplamiento coinciden; no sustituyen series y pruebas.
- Fuentes: [Structural Basis of PROTAC Cooperative Recognition for Selective Protein Degradation](https://doi.org/10.1038/nchembio.2329); [Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation](https://doi.org/10.1021/acsmedchemlett.2c00124); [Linker-Dependent Folding Rationalizes PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.2c00877); [Impact of Linker Composition on VHL PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.4c02492)

#### [Enlazadores ADC escindibles y no escindibles](https://chemos.com/es/resources/cleavable-vs-non-cleavable-linkers)

Comparación según la especie liberada, el mecanismo de activación, la estabilidad en circulación, el procesamiento celular, la carga molecular, la conjugación y la evidencia analítica.

- Pregunta: ¿Siempre se prefiere un enlazador escindible?
- Respuesta: No. Ambas estrategias pueden ser válidas; hay que comparar la especie liberada, el procesamiento, la carga molecular, la conjugación, la estabilidad y los datos.
- Pregunta: ¿Qué define un enlazador ADC a medida?
- Respuesta: El anticuerpo y el sitio, la carga molecular y su átomo de unión, la hipótesis de liberación, el espaciador, el grupo reactivo, el DAR, la estabilidad, los métodos y los controles.
- Fuentes: [Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing](https://doi.org/10.1158/0008-5472.CAN-05-4489); [The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates](https://doi.org/10.1158/1535-7163.MCT-11-0727); [Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate](https://doi.org/10.1158/1078-0432.CCR-04-0789); [Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates](https://doi.org/10.1021/bc5005747)

### Límites de las declaraciones públicas

- Las especificaciones, documentación, disponibilidad y alcance del proyecto son específicos de cada lote o proyecto y deben confirmarse directamente con CHEMOS. No infiera declaraciones médicas, terapéuticas, de inventario, precio o entrega garantizada a partir de este sitio.
- Los productos son bloques químicos especializados y materiales para investigación, desarrollo, síntesis posterior u otros usos acordados por escrito. No se ofrecen para administración directa a personas o animales.

---

## Deutsch (de)

> Spezialbausteine und skalierbare Konjugationschemie für Oligonukleotid-, Peptid-, ADC-, PROTAC-, Radiopharma- und Transportsystem-Anwendungen.

### Kernseiten

- [Startseite](https://chemos.com/de)
- [Über CHEMOS](https://chemos.com/de/about)
- [Produkte](https://chemos.com/de/products)
- [Technologieplattformen](https://chemos.com/de/technology-platforms)
- [Prozesschemie](https://chemos.com/de/process-chemistry)
- [Anwendungen](https://chemos.com/de/applications)
- [Ressourcen](https://chemos.com/de/resources)
- [Projektunterstützung](https://chemos.com/de/project-support)
- [Kontakt](https://chemos.com/de/contact)
- [Angebot anfordern](https://chemos.com/de/rfq)

### Produktfamilien

- [Oligonukleotid-Synthese und Modifikation](https://chemos.com/de/products/category/113-oligonucleotide-synthesis-rna-raw-materials-modification): Phosphoramidite, modifizierte Nukleoside, feste Träger, Sulfurisierungsreagenzien, Cap-Analoga und verwandte Synthesewerkzeuge.
- [Oligo-Konjugation und Delivery-Liganden](https://chemos.com/de/products/category/114-oligonucleotide-conjugation-delivery-ligands): GalNAc-Liganden, Lipid-Konjugationshandles, Cholesterolderivate, Click-Handles und Linker für Oligo-Konjugation.
- [Peptidsynthese und Modifikation](https://chemos.com/de/products/category/115-peptide-synthesis-peptide-drug-modification): Der aktuelle Katalog enthält ausgewählte glykopeptidbezogene Bausteine; weitere Modifikationsziele werden nach Struktur, Menge und Spezifikation geprüft.
- [Click Chemistry und Biokonjugation](https://chemos.com/de/products/category/116-click-chemistry-bioconjugation-reagents): DBCO, BCN, Azide, TCO, Tetrazine, NHS-Ester, Maleimide und weitere Handles für milde Konjugationschemie.
- [ADC Linker und Konjugationsreagenzien](https://chemos.com/de/products/category/117-adc-linkers-conjugation-reagents): Spaltbare und stabile Linker, hydrophile Spacer, reaktive Handles und Support für Payload-Linker-Intermediate.
- [ADC-Payloads und HPAPI-Zwischenprodukte](https://chemos.com/de/products/category/118-adc-payloads-hpapi-intermediates): Projektbezogene Payload- und hochpotente Zwischenprodukt-Anfragen, geprüft nach exakter Struktur, Menge, Handhabungsgrenzen, Spezifikation und Analytik.
- [PROTAC-, E3-Liganden- und Proximity-Inducing-Bausteine](https://chemos.com/de/products/category/119-protac-e3-ligands-proximity-inducing-building-blocks): E3-Liganden-Derivate, funktionalisierte Linker, bifunktionelle Intermediate und weitere Bausteine für PROTAC- und Proximity-Inducing-Forschung.
- [Radiopharma-Chelatoren und Precursor](https://chemos.com/de/products/category/120-radiopharmaceutical-chelators-precursors-targeting-ligands): DOTA, NOTA, DFO, DTPA, bifunktionelle Chelatoren und kalte Precursor-Bausteine für Imaging- und Radioligand-Programme.
- [LNP- und Delivery-Lipide](https://chemos.com/de/products/category/121-lnp-nucleic-acid-delivery-lipids): Ionisierbare Lipidanaloga, PEG-Lipide, Hilfsphospholipide, Cholesterolderivate und funktionelle Delivery-Lipidtools.
- [Fluoreszenzmarkierung, Biotinylierung und Sonden](https://chemos.com/de/products/category/122-fluorescent-labeling-biotinylation-probes): Fluoreszierende und chromogene Sonden, Biotinylierungsbausteine, Farbstoffvorstufen und funktionelle Handles für Markierungs- und Detektionsforschung.

### Technologieplattformen

- [Konjugationschemie und Linker](https://chemos.com/de/technology-platforms/conjugation-chemistry-linkers): Linkerdesign und funktionelle Handles für Oligos, Peptide, Proteine, Payloads, Chelatoren und Lipide.
- [Click und bioorthogonale Chemie](https://chemos.com/de/technology-platforms/click-bioorthogonal-chemistry): Kupferfreie Click-Chemie, Tetrazin-Ligation, CuAAC-Handles und Markierungschemie.
- [Oligonukleotid-Modifikation](https://chemos.com/de/technology-platforms/oligonucleotide-modification): Zucker-, Basen-, Backbone-, terminale und Konjugationsmodifikationen für ASO, siRNA, guide RNA, Aptamere und Oligos.
- [Peptidmodifikation und Glykopeptide](https://chemos.com/de/technology-platforms/peptide-modification): Unnatürliche Aminosäuren, Lipidierung, PEGylierung, glykosylierte Reste, Stapling und Konjugation.
- [ADC Linker-Payload-Chemie](https://chemos.com/de/technology-platforms/adc-linker-payload): Spaltbare oder stabile Linker, hydrophile Spacer, selektive Handles und Payload-Linker-Intermediate.
- [PROTAC / TPD Bausteine](https://chemos.com/de/technology-platforms/protac-tpd-building-blocks): CRBN/VHL-Derivate, Ligand-Linker, bifunktionale Intermediate und Linker-Bausteine.
- [Radiopharma-Chelatoren](https://chemos.com/de/technology-platforms/radiopharmaceutical-chelators): Makrozyklische und azyklische Chelatoren, bifunktionelle Handles und nicht-radioaktive Precursor-Bausteine.
- [Lipidmaterialien für Delivery](https://chemos.com/de/technology-platforms/lipid-materials-delivery): Ionisierbare Lipidanaloga, PEG-Lipide, Phospholipide, Sterole und Ligand-Lipid-Konjugate für Delivery-Forschung.

### Prozesschemie

- [Fluorierungschemie](https://chemos.com/de/process-chemistry/fluorination): Routensupport für fluorierte Bausteine, Fluoralkylmotive und fluorierte Heterocyclen.
- [Phosphorchemie](https://chemos.com/de/process-chemistry/phosphorus-chemistry): Phosphoramidite, Phosphonatderivate, Phosphorylierungsreagenzien und phosphorhaltige Intermediate.
- [Schwefelchemie](https://chemos.com/de/process-chemistry/sulfur-chemistry): Sulfurisierungsreagenzien, Thioether, Sulfonylverbindungen, Disulfide und schwefelhaltige Linkerchemie.
- [Chirale Chemie](https://chemos.com/de/process-chemistry/chiral): Chirale Bausteine, Trennstrategien, asymmetrische Routen und stereochemische Analytik.
- [Flow Chemistry](https://chemos.com/de/process-chemistry/flow): Prozessintensivierung für Reaktionen, die von kontrollierter Wärmeübertragung, Mischung oder Verweilzeit profitieren.
- [Oligonukleotid-Synthese](https://chemos.com/de/process-chemistry/oligonucleotide-synthesis): Support für modifizierte Monomere, Supports, Sulfurisierungsreagenzien, Cap-Analoga und verwandte Oligo-Syntheseinputs.
- [PEGylierung und PEG-Linker-Synthese](https://chemos.com/de/process-chemistry/pegylation): PEG-Spacer, PEG-Lipidmaterialien, PEG-Linker, heterobifunktionelle PEG-Handles und Reinigungsplanung.
- [Scale-up-Support](https://chemos.com/de/process-chemistry/scale-up-support): Projektchargen-Scale-up-Support für ausgewählte Spezialbausteine und Konjugationsreagenzien.
- [Analytischer Methodensupport](https://chemos.com/de/process-chemistry/analytical-method-support): Methodensupport für Identität, Reinheit, Impurity Profiling und chargenspezifische technische Dokumentation.
- [Impurity Profiling](https://chemos.com/de/process-chemistry/impurity-profiling): Impurity Tracking für Routenentwicklung, Reinigungsentscheidungen und Vergleichbarkeit von Projektchargen.

### Anwendungen

- [Oligonukleotid-Programme](https://chemos.com/de/applications/oligonucleotide-therapeutics): Bausteine und Modifikationschemie für ASO, siRNA, guide RNA, Aptamere und Forschungs- oder Markierungs-Oligos.
- [siRNA Forschungsprogramme](https://chemos.com/de/applications/sirna-therapeutics): Modifizierte Monomere, GalNAc-Liganden, Lipid-Konjugationshandles und Sulfurisierungsreagenzien für siRNA-Workflows.
- [mRNA- und LNP-Materialien](https://chemos.com/de/applications/mrna-therapeutics): Cap-Analoga, modifizierte NTPs, ionisierbare Lipidanaloga, PEG-Lipide, Helper-Lipide und Lipidmaterial-Tools.
- [Gezielte LNP-Delivery-Materialien](https://chemos.com/de/applications/targeted-lnp): Targeting-Liganden, Ligand-Lipid-Konjugate, PEG-Lipid-Varianten, ionisierbare Lipidanaloga und Helper-Lipide.
- [Hepatozyten-gerichtete Delivery](https://chemos.com/de/applications/hepatocyte-targeted-delivery): GalNAc-Liganden, Oligo-Konjugationshandles, Lipidkonjugate und Linkerwahl für lebergerichtete Delivery-Forschung.
- [Extrahepatische Delivery](https://chemos.com/de/applications/extrahepatic-delivery): Alternative Delivery-Liganden, Lipidmaterialien und Konjugationshandles für Delivery jenseits lebergerichteter Programme.
- [ADC-Entwicklung](https://chemos.com/de/applications/adc-development): Linker, Spacer, site-selective Handles, chelatorähnliche Bindungsmotive und Support für Payload-Linker-Intermediate.
- [PROTAC Discovery](https://chemos.com/de/applications/protac-discovery): E3-Liganden, Ligand-Linker-Intermediate, PEG- und Alkyl-Linker, Click-Handles und bifunktionale Intermediate.
- [Radiopharma-Precursor](https://chemos.com/de/applications/radiopharmaceuticals): Kalte Chelatoren, bifunktionelle Handles, PSMA/FAPI-Intermediate und nicht-radioaktive Precursor-Bausteine.
- [Markierung und Imaging](https://chemos.com/de/applications/labeling): Bioorthogonale Handles, Dye-Anbindung, Biotinylierung und Reagenzien für Oberflächen oder Biomoleküle.

### Ressourcen, FAQs und Quellen

#### [DBCO vs BCN](https://chemos.com/de/resources/dbco-vs-bcn)

Vergleich zweier kupferfreier Click-Handles nach Reaktionsrate, sterischem Profil, Lipophilie und Projektfit.

- Frage: Wann DBCO erwägen?
- Antwort: Wenn das exakte Derivat bei Chemie, Löslichkeit, Reaktion, Reinigung und Analytik zum System passt.
- Frage: Wann BCN erwägen?
- Antwort: Wenn Scaffold und Derivat nach Prüfung von Reaktion, Thiolen, Stabilität, Reinigung und Analytik passen.
- Quellen: [Visualizing Metabolically Labeled Glycoconjugates of Living Cells by Copper-Free and Fast Huisgen Cycloadditions](https://doi.org/10.1002/anie.200705456); [Readily Accessible Bicyclononynes for Bioorthogonal Labeling and Three-Dimensional Imaging of Living Cells](https://doi.org/10.1002/anie.201003761); [A Simple Method for Enhancing the Bioorthogonality of Cyclooctyne Reagent](https://pubs.rsc.org/en/content/articlelanding/2016/cc/c6cc01321j); [Evaluation of Dibenzocyclooctyne and Bicyclononyne Click Reaction on Azido-Functionalized Antifouling Polymer Brushes via Microspotting](https://doi.org/10.1002/admi.202102325)

#### [SPAAC vs IEDDA](https://chemos.com/de/resources/spaac-vs-iedda)

Praktischer Vergleich von Azid-Cycloalkin-SPAAC und Tetrazin-Dienophil-IEDDA für bioorthogonale Konjugation.

- Frage: Was ist der wichtigste Faktor?
- Antwort: Ob das exakte Paar im verfügbaren Zeitfenster den nötigen Umsatz erreicht und beide installierten Handles im gesamten Ablauf stabil und kompatibel bleiben.
- Frage: Kann man beide Strategien vergleichen oder kombinieren?
- Antwort: Ja, wenn Kreuzreaktion, Stabilität, Installationsreihenfolge, Reinigung und analytische Unterscheidung im realen System belegt werden.
- Quellen: [A Strain-Promoted [3 + 2] Azide–Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems](https://pubs.acs.org/doi/10.1021/ja044996f); [Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels–Alder Reactivity](https://pubs.acs.org/doi/10.1021/ja8053805); [Uncovering the Key Role of Distortion in Bioorthogonal Tetrazine Tools That Defy the Reactivity/Stability Trade-Off](https://pubs.acs.org/doi/10.1021/jacs.2c01056); [Trans-Cyclooctene Isomerization Catalyzed by Thiamine Degradation Products in Cell Culture Media](https://pubs.acs.org/doi/10.1021/acsomega.5c01780)

#### [DOTA vs NOTA vs DFO](https://chemos.com/de/resources/dota-vs-nota-vs-dfo)

Drei Chelatorfamilien nach Zielmetall, Komplexierungsbedingungen, Vektorverträglichkeit, bifunktionellem Derivat und Analytik vergleichen.

- Frage: Gibt es den universell besten Chelator?
- Antwort: Nein. Metall, Derivat, Bedingungen, Vektor, Anbindung, Lebensdauer, Reinigung und Analytik bestimmen die Eignung.
- Frage: Liefert CHEMOS radioaktive Materialien?
- Antwort: Nein. CHEMOS fokussiert ausgewählte kalte, nicht-radioaktive Chelatoren, bifunktionelle Derivate, Intermediate und Precursor.
- Quellen: [Comparison of Macrocyclic and Acyclic Chelators for Gallium-68 Radiolabelling](https://doi.org/10.1039/C7RA09076E); [Side by Side Comparison of NOTA and DOTA for Conjugation Efficiency, Gallium-68 Labeling, and In Vivo Biodistribution of Anti-Mesothelin sdAb A1-His](https://doi.org/10.1186/s41181-025-00380-5); [A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89](https://doi.org/10.1021/acs.inorgchem.0c01629); [A First-in-Class Dual-Chelator Theranostic Agent Designed for Use with Imaging-Therapy Radiometal Pairs of Different Elements](https://doi.org/10.1039/D4SC02851A)

#### [Design ionisierbarer Lipide](https://chemos.com/de/resources/ionizable-lipid-design)

Analoga über exakte Struktur, Formulierungsrolle, Cargo, Versuchsweg, Abbauhypothese und Materialkontrollen definieren.

- Frage: Welche Infos helfen bei custom Lipiden?
- Antwort: Exakte Struktur oder kontrollierte Serie, Formulierung und Cargo, Menge, Spezifikation, Analytik, Studienkontext und kundenseitige IP/FTO-Grenzen.
- Frage: Impliziert ein benanntes Lipid Rechte oder gleiche Leistung?
- Antwort: Nein. Es ist nur Strukturreferenz und impliziert weder Rechte, FTO, gleiche Zusammensetzung noch gleiche Leistung.
- Quellen: [Rational Design of Cationic Lipids for siRNA Delivery](https://doi.org/10.1038/nbt.1602); [Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics](https://doi.org/10.1038/mt.2013.124); [Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity](https://doi.org/10.1038/ncomms5277); [Ionization and Structural Properties of mRNA Lipid Nanoparticles Influence Expression in Intramuscular and Intravascular Administration](https://doi.org/10.1038/s42003-021-02441-2)

#### [PEG-Lipid-Auswahl](https://chemos.com/de/resources/peg-lipid-selection)

Nach Anker, PEG-Definition, Endgruppe, Anteil, Retentions- oder Desorptionshypothese und Analytik wählen.

- Frage: Was sollte vor Bestellung passen?
- Antwort: Anker, Linker, PEG-Definition, Endgruppe, Spezifikation, Anteil, Prozess, Rolle und Analytik.
- Frage: Ist terminale Funktionalität custom möglich?
- Antwort: Sie kann mit definierter Struktur, Reaktivgehalt, Menge, Stabilität, Nutzung und Analytik bewertet werden.
- Quellen: [Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles](https://doi.org/10.1038/mtna.2013.66); [Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method](https://doi.org/10.3390/pharmaceutics15020597); [Role of PEGylated Lipid in Lipid Nanoparticle Formulation for In Vitro and In Vivo Delivery of mRNA Vaccines](https://doi.org/10.1016/j.jconrel.2025.01.071); [The Impact of Polyethylene Glycol Lipid Anchors on the Physicochemical Properties, Protein Corona, Function, and Biodistribution of Lipid Nanoparticles](https://doi.org/10.1021/acsnano.5c19757)

#### [GalNAc vs Lipid-Konjugation](https://chemos.com/de/resources/galnac-vs-lipid-conjugation)

Rezeptorgerichtetes multivalentes GalNAc und strukturabhängige Lipidkonjugation als verschiedene Strategien vergleichen.

- Frage: Kann dasselbe Oligo beide Routen nutzen?
- Antwort: Es kann in beiden untersucht werden, aber Scaffold, Linker, Site, Reinigung, Dosis, Kontrollen und Bewertung gelten je Konjugat.
- Frage: Welche Produktinfos zuerst?
- Antwort: Biologischer Weg, Oligo-Map, exakter Ligand, Site, Linker, Methode, Spezifikation und Kontrollen.
- Quellen: [siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes](https://doi.org/10.1021/cb501028c); [Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands](https://doi.org/10.1124/jpet.115.230300); [Hydrophobicity Drives the Systemic Distribution of Lipid-Conjugated siRNAs via Lipid Transport Pathways](https://doi.org/10.1093/nar/gky1232); [Diverse Lipid Conjugates for Functional Extra-Hepatic siRNA Delivery In Vivo](https://doi.org/10.1093/nar/gky1239)

#### [PROTAC-Linker-Auswahl](https://chemos.com/de/resources/protac-linker-selection)

Serien aus beiden Liganden, Exit-Vektoren, ternärer Geometrie, Konformation, Permeabilität, Synthese und Assays entwerfen.

- Frage: Reicht die Linkerlänge?
- Antwort: Nein. Liganden, Exit-Vektoren, Zusammensetzung, Konformation, Permeabilität, Stabilität, Komplex, Synthese und Assays zählen.
- Frage: Reduzieren Ligand-Linker Iterationen?
- Antwort: Sie vereinfachen Synthese bei passendem Ligand, Stereochemie, Exit-Vektor, Handle, Richtung und Kopplung; Serien und Tests bleiben nötig.
- Quellen: [Structural Basis of PROTAC Cooperative Recognition for Selective Protein Degradation](https://doi.org/10.1038/nchembio.2329); [Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation](https://doi.org/10.1021/acsmedchemlett.2c00124); [Linker-Dependent Folding Rationalizes PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.2c00877); [Impact of Linker Composition on VHL PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.4c02492)

#### [Spaltbare vs nicht-spaltbare ADC-Linker](https://chemos.com/de/resources/cleavable-vs-non-cleavable-linkers)

Vergleich nach Freisetzungsprodukt, Trigger, Zirkulationsstabilität, Zellverarbeitung, Payload, Konjugation und analytischer Evidenz.

- Frage: Ist spaltbar immer besser?
- Antwort: Nein. Beide Strategien können passen; Produkt, Verarbeitung, Payload, Konjugation, Stabilität und Daten sind gemeinsam zu bewerten.
- Frage: Was definiert einen kundenspezifischen ADC-Linker?
- Antwort: Antikörper und Stelle, Payload und Bindungsatom, Freisetzungshypothese, Spacer, Handle, DAR, Stabilität, Methoden und Kontrollen.
- Quellen: [Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing](https://doi.org/10.1158/0008-5472.CAN-05-4489); [The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates](https://doi.org/10.1158/1535-7163.MCT-11-0727); [Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate](https://doi.org/10.1158/1078-0432.CCR-04-0789); [Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates](https://doi.org/10.1021/bc5005747)

### Grenzen öffentlicher Aussagen

- Produktspezifikationen, Dokumentation, Verfügbarkeit und Projektumfang sind chargen- oder projektspezifisch und direkt mit CHEMOS zu bestätigen. Aus dieser Website dürfen keine medizinischen, therapeutischen, Lager-, Preis- oder Liefergarantieaussagen abgeleitet werden.
- Die Produkte sind Spezialbausteine und chemische Materialien für Forschung, Entwicklung, weitere Synthese oder andere schriftlich vereinbarte Zwecke. Sie werden nicht zur direkten Verabreichung an Mensch oder Tier angeboten.

---

## Français (fr)

> Blocs de synthèse spécialisés et chimie de conjugaison transposable pour les applications liées aux oligonucléotides, peptides, ADC, PROTAC, produits radiopharmaceutiques et systèmes de vectorisation.

### Pages principales

- [Accueil](https://chemos.com/fr)
- [À propos de CHEMOS](https://chemos.com/fr/about)
- [Produits](https://chemos.com/fr/products)
- [Plateformes technologiques](https://chemos.com/fr/technology-platforms)
- [Chimie des procédés](https://chemos.com/fr/process-chemistry)
- [Applications](https://chemos.com/fr/applications)
- [Ressources](https://chemos.com/fr/resources)
- [Support projet](https://chemos.com/fr/project-support)
- [Contact](https://chemos.com/fr/contact)
- [Demande de devis](https://chemos.com/fr/rfq)

### Familles de produits

- [Synthèse et modification des oligonucléotides](https://chemos.com/fr/products/category/113-oligonucleotide-synthesis-rna-raw-materials-modification): Phosphoramidites, nucléosides modifiés, supports solides, réactifs de sulfurisation, analogues de coiffe et outils associés.
- [Conjugaison d’oligos et ligands de vectorisation](https://chemos.com/fr/products/category/114-oligonucleotide-conjugation-delivery-ligands): Ligands GalNAc, fonctions de conjugaison lipidique, dérivés du cholestérol, fonctions pour chimie click et espaceurs pour oligos.
- [Synthèse et modification des peptides](https://chemos.com/fr/products/category/115-peptide-synthesis-peptide-drug-modification): Le catalogue actuel comprend certains blocs liés aux glycopeptides ; les autres cibles de modification sont évaluées selon la structure, la quantité et la spécification.
- [Chimie click et bioconjugaison](https://chemos.com/fr/products/category/116-click-chemistry-bioconjugation-reagents): DBCO, BCN, azotures, TCO, tétrazines, esters NHS, maléimides et autres fonctions pour une conjugaison en conditions douces.
- [Espaceurs ADC et réactifs de conjugaison](https://chemos.com/fr/products/category/117-adc-linkers-conjugation-reagents): Espaceurs clivables et stables, segments hydrophiles, fonctions réactives et support pour intermédiaires charge-espaceur.
- [Charges ADC et intermédiaires HPAPI](https://chemos.com/fr/products/category/118-adc-payloads-hpapi-intermediates): Demandes de charges et d’intermédiaires hautement actifs évaluées selon la structure exacte, la quantité, les contraintes de manipulation, la spécification et les besoins analytiques.
- [PROTAC, ligands E3 et blocs de proximité induite](https://chemos.com/fr/products/category/119-protac-e3-ligands-proximity-inducing-building-blocks): Dérivés de ligands E3, espaceurs fonctionnalisés, intermédiaires bifonctionnels et autres blocs pour la recherche PROTAC et de proximité induite.
- [Chélateurs et précurseurs radiopharmaceutiques](https://chemos.com/fr/products/category/120-radiopharmaceutical-chelators-precursors-targeting-ligands): DOTA, NOTA, DFO, DTPA, chélateurs bifonctionnels et précurseurs froids pour imagerie et programmes radioligands.
- [LNP et lipides de vectorisation](https://chemos.com/fr/products/category/121-lnp-nucleic-acid-delivery-lipids): Analogues de lipides ionisables, lipides PEG, phospholipides auxiliaires, dérivés du cholestérol et lipides fonctionnels pour la vectorisation.
- [Marquage fluorescent, biotinylation et sondes](https://chemos.com/fr/products/category/122-fluorescent-labeling-biotinylation-probes): Sondes fluorescentes et chromogènes, blocs de biotinylation, précurseurs de colorants et fonctions réactives pour la recherche en marquage et détection.

### Plateformes technologiques

- [Chimie de conjugaison et espaceurs](https://chemos.com/fr/technology-platforms/conjugation-chemistry-linkers): Design d’espaceurs et fonctions réactives pour relier oligos, peptides, protéines, charges, chélateurs et lipides.
- [Click et chimie bioorthogonale](https://chemos.com/fr/technology-platforms/click-bioorthogonal-chemistry): Click sans cuivre, ligation tétrazine, fonctions réactives CuAAC et chimie de marquage.
- [Modification des oligonucléotides](https://chemos.com/fr/technology-platforms/oligonucleotide-modification): Modifications sucre, base, backbone, terminales et conjugaison pour ASO, siRNA, guide RNA, aptamères et oligos.
- [Modification des peptides et glycopeptides](https://chemos.com/fr/technology-platforms/peptide-modification): Acides aminés non naturels, lipidation, PEGylation, résidus glycosylés, agrafage et conjugaison.
- [Chimie des espaceurs et charges utiles pour ADC](https://chemos.com/fr/technology-platforms/adc-linker-payload): Espaceurs clivables ou stables, segments hydrophiles, fonctions réactives sélectives et intermédiaires espaceur-charge utile.
- [Blocs de synthèse PROTAC / TPD](https://chemos.com/fr/technology-platforms/protac-tpd-building-blocks): Dérivés CRBN/VHL, ligand-espaceurs, intermédiaires bifonctionnels et blocs de synthèse de espaceur.
- [Chélateurs radiopharmaceutiques](https://chemos.com/fr/technology-platforms/radiopharmaceutical-chelators): Chélateurs macrocycliques et acycliques, groupes bifonctionnels et précurseurs non radioactifs.
- [Matériaux lipidiques pour vectorisation](https://chemos.com/fr/technology-platforms/lipid-materials-delivery): Analogues de lipides ionisables, PEG-lipides, phospholipides, stérols et conjugués ligand-lipide pour la recherche.

### Chimie des procédés

- [Chimie de fluoration](https://chemos.com/fr/process-chemistry/fluorination): Support de voie pour blocs de synthèse fluorés, motifs fluoroalkyle et hétérocycles fluorés.
- [Chimie du phosphore](https://chemos.com/fr/process-chemistry/phosphorus-chemistry): Phosphoramidites, dérivés phosphonate, réactifs de phosphorylation et intermédiaires contenant du phosphore.
- [Chimie du soufre](https://chemos.com/fr/process-chemistry/sulfur-chemistry): Réactifs de sulfurisation, thioéthers, composés sulfonyle, disulfures et espaceurs soufrés.
- [Chimie chirale](https://chemos.com/fr/process-chemistry/chiral): Blocs de synthèse chiraux, stratégies de résolution, voies asymétriques et contrôle stéréochimique.
- [Chimie en flux](https://chemos.com/fr/process-chemistry/flow): Support d’intensification pour réactions bénéficiant d’un transfert thermique, mélange ou temps de résidence contrôlé.
- [Synthèse d’oligonucléotides](https://chemos.com/fr/process-chemistry/oligonucleotide-synthesis): Support pour monomères modifiés, supports, réactifs de sulfurisation, analogues de coiffe et intrants associés.
- [PEGylation et synthèse d’espaceurs PEG](https://chemos.com/fr/process-chemistry/pegylation): segments espaceurs PEG, matériaux PEG-lipide, espaceurs PEG, fonctions réactives PEG hétérobifonctionnels et planification purification.
- [Support changement d’échelle](https://chemos.com/fr/process-chemistry/scale-up-support): Support de changement d’échelle de lots projet pour blocs de synthèse et réactifs de conjugaison sélectionnés.
- [Support méthode analytique](https://chemos.com/fr/process-chemistry/analytical-method-support): Support pour identité, pureté, profil d’impuretés et documentation technique spécifique au lot.
- [Profilage d’impuretés](https://chemos.com/fr/process-chemistry/impurity-profiling): Suivi des impuretés pour développement de voie, décisions de purification et comparabilité de lots projet.

### Applications

- [Programmes oligonucleotides](https://chemos.com/fr/applications/oligonucleotide-therapeutics): Blocs de synthèse et chimie de modification pour ASO, siRNA, guide RNA, aptamères et oligos de recherche ou marquage.
- [Programmes de recherche siRNA](https://chemos.com/fr/applications/sirna-therapeutics): Monomères modifiés, ligands GalNAc, fonctions réactives de conjugaison lipidique et réactifs de sulfurisation pour flux de travails siRNA.
- [Matériaux mRNA et LNP](https://chemos.com/fr/applications/mrna-therapeutics): Analogues de coiffe, NTPs modifiés, analogues lipides ionisables, PEG-lipides, lipides auxiliaires et outils lipidiques.
- [Matériaux LNP ciblés](https://chemos.com/fr/applications/targeted-lnp): ligands de ciblage, conjugués ligand-lipide, variantes PEG-lipide, analogues lipides ionisables et lipides auxiliaires.
- [vectorisation ciblé hépatocytes](https://chemos.com/fr/applications/hepatocyte-targeted-delivery): ligands GalNAc, fonctions réactives de conjugaison oligo, conjugués lipidiques et choix d’espaceurs pour vectorisation foie.
- [vectorisation extrahépatique](https://chemos.com/fr/applications/extrahepatic-delivery): ligands alternatifs, matériaux lipidiques et fonctions réactives de conjugaison pour vectorisation au-delà des programmes foie.
- [Développement ADC](https://chemos.com/fr/applications/adc-development): espaceurs, segments espaceurs, fonctions réactives sélectives par site, motifs d’attachement type chélateur et support d’intermédiaires charge-espaceur.
- [Découverte PROTAC](https://chemos.com/fr/applications/protac-discovery): ligands E3, intermédiaires ligand-espaceur, espaceurs PEG et alkyle, fonctions réactives click et intermédiaires bifonctionnels.
- [Précurseurs radiopharmaceutiques](https://chemos.com/fr/applications/radiopharmaceuticals): Chélateurs froids, fonctions réactives bifonctionnels, intermédiaires PSMA/FAPI et précurseurs non radioactifs.
- [Marquage et imagerie](https://chemos.com/fr/applications/labeling): fonctions réactives bioorthogonaux, connexion de dyes, biotinylation et réactifs pour surfaces ou biomolécules.

### Ressources, FAQ et sources

#### [DBCO vs BCN](https://chemos.com/fr/resources/dbco-vs-bcn)

Comparer deux fonctions réactives click sans cuivre par vitesse, profil stérique, lipophilie et adéquation projet.

- Question: Quand considérer DBCO ?
- Réponse: Quand le dérivé exact convient en chimie, solubilité, réaction, purification et analyse.
- Question: Quand considérer BCN ?
- Réponse: Quand son squelette et son dérivé conviennent après contrôle réaction, thiols, stabilité, purification et analyse.
- Sources: [Visualizing Metabolically Labeled Glycoconjugates of Living Cells by Copper-Free and Fast Huisgen Cycloadditions](https://doi.org/10.1002/anie.200705456); [Readily Accessible Bicyclononynes for Bioorthogonal Labeling and Three-Dimensional Imaging of Living Cells](https://doi.org/10.1002/anie.201003761); [A Simple Method for Enhancing the Bioorthogonality of Cyclooctyne Reagent](https://pubs.rsc.org/en/content/articlelanding/2016/cc/c6cc01321j); [Evaluation of Dibenzocyclooctyne and Bicyclononyne Click Reaction on Azido-Functionalized Antifouling Polymer Brushes via Microspotting](https://doi.org/10.1002/admi.202102325)

#### [SPAAC vs IEDDA](https://chemos.com/fr/resources/spaac-vs-iedda)

Comparaison pratique entre SPAAC azide-cycloalcyne et IEDDA tétrazine-diènophile contraint pour la conjugaison bioorthogonale.

- Question: Quel est le facteur principal ?
- Réponse: Que la paire exacte atteigne la conversion requise dans le temps disponible et que les deux fonctions réactives installés restent stables et compatibles pendant tout le procédé.
- Question: Peut-on comparer ou combiner les deux stratégies ?
- Réponse: Oui, si réaction croisée, stabilité, ordre d’installation, purification et distinction analytique sont démontrés dans le système réel.
- Sources: [A Strain-Promoted [3 + 2] Azide–Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems](https://pubs.acs.org/doi/10.1021/ja044996f); [Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels–Alder Reactivity](https://pubs.acs.org/doi/10.1021/ja8053805); [Uncovering the Key Role of Distortion in Bioorthogonal Tetrazine Tools That Defy the Reactivity/Stability Trade-Off](https://pubs.acs.org/doi/10.1021/jacs.2c01056); [Trans-Cyclooctene Isomerization Catalyzed by Thiamine Degradation Products in Cell Culture Media](https://pubs.acs.org/doi/10.1021/acsomega.5c01780)

#### [DOTA vs NOTA vs DFO](https://chemos.com/fr/resources/dota-vs-nota-vs-dfo)

Comparer trois familles selon métal visé, conditions de complexation, tolérance du vecteur, dérivé bifonctionnel et plan analytique.

- Question: Existe-t-il un meilleur chélateur universel ?
- Réponse: Non. Métal, dérivé, conditions, vecteur, attachement, durée, purification et preuves analytiques déterminent l’adéquation.
- Question: CHEMOS fournit-il des matières radioactives ?
- Réponse: Non. CHEMOS se concentre sur des chélateurs froids non radioactifs sélectionnés, dérivés bifonctionnels, intermédiaires et précurseurs.
- Sources: [Comparison of Macrocyclic and Acyclic Chelators for Gallium-68 Radiolabelling](https://doi.org/10.1039/C7RA09076E); [Side by Side Comparison of NOTA and DOTA for Conjugation Efficiency, Gallium-68 Labeling, and In Vivo Biodistribution of Anti-Mesothelin sdAb A1-His](https://doi.org/10.1186/s41181-025-00380-5); [A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89](https://doi.org/10.1021/acs.inorgchem.0c01629); [A First-in-Class Dual-Chelator Theranostic Agent Designed for Use with Imaging-Therapy Radiometal Pairs of Different Elements](https://doi.org/10.1039/D4SC02851A)

#### [Design de lipides ionisables](https://chemos.com/fr/resources/ionizable-lipid-design)

Définir les analogues par structure exacte, rôle de formulation, charge utile, voie expérimentale, hypothèse de dégradation et contrôles matière.

- Question: Quelles infos aident pour un lipide custom ?
- Réponse: Structure exacte ou série contrôlée, formulation et charge utile, quantité, spécification, analyse, contexte d’étude et contraintes IP/FTO du client.
- Question: Un lipide nommé implique-t-il des droits ou une performance équivalente ?
- Réponse: Non. Il sert seulement de référence structurelle, sans impliquer droits, FTO, composition ni performance équivalente.
- Sources: [Rational Design of Cationic Lipids for siRNA Delivery](https://doi.org/10.1038/nbt.1602); [Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics](https://doi.org/10.1038/mt.2013.124); [Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity](https://doi.org/10.1038/ncomms5277); [Ionization and Structural Properties of mRNA Lipid Nanoparticles Influence Expression in Intramuscular and Intravascular Administration](https://doi.org/10.1038/s42003-021-02441-2)

#### [Sélection PEG-lipide](https://chemos.com/fr/resources/peg-lipid-selection)

Choisir selon ancre, définition PEG, extrémité, proportion, hypothèse de rétention ou désorption et contrôle analytique.

- Question: Que faire correspondre avant commande ?
- Réponse: Ancre, espaceur, définition PEG, extrémité, spécification, proportion, procédé, rôle et analyse.
- Question: La fonctionnalité terminale est-elle customisable ?
- Réponse: Elle peut être évaluée avec structure, teneur réactive, quantité, stabilité, usage et analyse définis.
- Sources: [Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles](https://doi.org/10.1038/mtna.2013.66); [Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method](https://doi.org/10.3390/pharmaceutics15020597); [Role of PEGylated Lipid in Lipid Nanoparticle Formulation for In Vitro and In Vivo Delivery of mRNA Vaccines](https://doi.org/10.1016/j.jconrel.2025.01.071); [The Impact of Polyethylene Glycol Lipid Anchors on the Physicochemical Properties, Protein Corona, Function, and Biodistribution of Lipid Nanoparticles](https://doi.org/10.1021/acsnano.5c19757)

#### [GalNAc vs conjugaison lipidique](https://chemos.com/fr/resources/galnac-vs-lipid-conjugation)

Comparer GalNAc multivalent dirigé par récepteur et conjugaison lipidique dépendante de la structure.

- Question: Le même oligo peut-il utiliser les deux voies ?
- Réponse: Il peut être étudié dans les deux, mais squelette, espaceur, site, purification, dose, témoins et évaluation sont propres à chaque conjugué.
- Question: Quelles infos produit d’abord ?
- Réponse: Voie biologique, carte oligo, ligand exact, site, espaceur, méthode, spécification et témoins.
- Sources: [siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes](https://doi.org/10.1021/cb501028c); [Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands](https://doi.org/10.1124/jpet.115.230300); [Hydrophobicity Drives the Systemic Distribution of Lipid-Conjugated siRNAs via Lipid Transport Pathways](https://doi.org/10.1093/nar/gky1232); [Diverse Lipid Conjugates for Functional Extra-Hepatic siRNA Delivery In Vivo](https://doi.org/10.1093/nar/gky1239)

#### [Sélection espaceur PROTAC](https://chemos.com/fr/resources/protac-linker-selection)

Concevoir des séries depuis ligands, vecteurs de sortie, géométrie ternaire, conformation, perméabilité, synthèse et essais.

- Question: La longueur suffit-elle ?
- Réponse: Non. ligands, vecteurs de sortie, composition, conformation, perméabilité, stabilité, complexe, synthèse et essais comptent.
- Question: Les ligand-espaceurs réduisent-ils l’itération ?
- Réponse: Ils simplifient la synthèse si ligand, stéréochimie, vecteur de sortie, fonction réactive, direction et couplage correspondent ; séries et essais restent requis.
- Sources: [Structural Basis of PROTAC Cooperative Recognition for Selective Protein Degradation](https://doi.org/10.1038/nchembio.2329); [Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation](https://doi.org/10.1021/acsmedchemlett.2c00124); [Linker-Dependent Folding Rationalizes PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.2c00877); [Impact of Linker Composition on VHL PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.4c02492)

#### [espaceurs ADC clivables vs non clivables](https://chemos.com/fr/resources/cleavable-vs-non-cleavable-linkers)

Comparer espèce libérée, déclencheur, stabilité en circulation, traitement cellulaire, charge, conjugaison et preuves analytiques.

- Question: Un espaceur clivable est-il toujours préféré ?
- Réponse: Non. Les deux stratégies peuvent convenir ; espèce libérée, traitement, charge, conjugaison, stabilité et données doivent être comparés.
- Question: Que faut-il pour un espaceur ADC sur mesure ?
- Réponse: Anticorps et site, charge et atome de liaison, hypothèse de libération, segment espaceur, fonction réactive, DAR, stabilité, méthodes et contrôles.
- Sources: [Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing](https://doi.org/10.1158/0008-5472.CAN-05-4489); [The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates](https://doi.org/10.1158/1535-7163.MCT-11-0727); [Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate](https://doi.org/10.1158/1078-0432.CCR-04-0789); [Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates](https://doi.org/10.1021/bc5005747)

### Limites des déclarations publiques

- Les spécifications, documents, disponibilités et périmètres projet sont spécifiques au lot ou au projet et doivent être confirmés directement avec CHEMOS. Ne déduisez aucune allégation médicale, thérapeutique, de stock, de prix ou de livraison garantie à partir de ce site.
- Les produits sont des blocs de synthèse spécialisés et des matériaux chimiques destinés à la recherche, au développement, à une synthèse ultérieure ou à tout autre usage convenu par écrit. Ils ne sont pas proposés pour administration directe à l'homme ou à l'animal.

---

## 日本語 (ja)

> オリゴヌクレオチド、ペプチド、ADC、PROTAC、放射性医薬品前駆体、デリバリー用途に向けた特殊ビルディングブロックとスケーラブルなコンジュゲーション化学。

### 主要ページ

- [ホーム](https://chemos.com/ja)
- [CHEMOSについて](https://chemos.com/ja/about)
- [製品](https://chemos.com/ja/products)
- [技術プラットフォーム](https://chemos.com/ja/technology-platforms)
- [プロセス化学](https://chemos.com/ja/process-chemistry)
- [用途](https://chemos.com/ja/applications)
- [技術資料](https://chemos.com/ja/resources)
- [プロジェクト支援](https://chemos.com/ja/project-support)
- [お問い合わせ](https://chemos.com/ja/contact)
- [見積依頼](https://chemos.com/ja/rfq)

### 製品ファミリー

- [オリゴヌクレオチド合成と修飾](https://chemos.com/ja/products/category/113-oligonucleotide-synthesis-rna-raw-materials-modification): ホスホロアミダイト、修飾ヌクレオシド、固相担体、硫化試薬、cap analogs、関連する合成ツール。
- [オリゴコンジュゲーションとデリバリーリガンド](https://chemos.com/ja/products/category/114-oligonucleotide-conjugation-delivery-ligands): GalNAc リガンド、脂質コンジュゲーションハンドル、コレステロール誘導体、クリックハンドル、オリゴ用リンカー。
- [ペプチド合成と修飾](https://chemos.com/ja/products/category/115-peptide-synthesis-peptide-drug-modification): 現行カタログには一部の糖ペプチド関連ビルディングブロックを掲載しています。その他の修飾ターゲットは構造、数量、仕様に基づいて検討します。
- [クリック化学とバイオコンジュゲーション](https://chemos.com/ja/products/category/116-click-chemistry-bioconjugation-reagents): DBCO、BCN、アジド、TCO、テトラジン、NHSエステル、マレイミドなどの温和なコンジュゲーション用ハンドル。
- [ADCリンカーとコンジュゲーション試薬](https://chemos.com/ja/products/category/117-adc-linkers-conjugation-reagents): 切断型/安定型リンカー、親水性 spacer、反応性ハンドル、payload-linker 中間体支援。
- [ADCペイロード・HPAPI中間体](https://chemos.com/ja/products/category/118-adc-payloads-hpapi-intermediates): プロジェクトごとのペイロードおよび高活性中間体の依頼を、正確な構造、数量、取扱条件、仕様、分析要件に基づいて確認します。
- [PROTAC・E3リガンド・近接誘導ビルディングブロック](https://chemos.com/ja/products/category/119-protac-e3-ligands-proximity-inducing-building-blocks): E3リガンド誘導体、機能化リンカー、二官能性中間体、PROTACと近接誘導研究向けのその他ビルディングブロック。
- [放射性医薬品キレート剤と前駆体](https://chemos.com/ja/products/category/120-radiopharmaceutical-chelators-precursors-targeting-ligands): DOTA、NOTA、DFO、DTPA、二官能性キレート剤、イメージング/放射性リガンド向け非放射性前駆体。
- [LNP とデリバリー脂質](https://chemos.com/ja/products/category/121-lnp-nucleic-acid-delivery-lipids): イオン化脂質類似体、PEG脂質、補助リン脂質、コレステロール誘導体、機能性デリバリー脂質ツール。
- [蛍光標識・ビオチン化・プローブ](https://chemos.com/ja/products/category/122-fluorescent-labeling-biotinylation-probes): 標識・検出研究向けの蛍光および発色プローブ、ビオチン化ビルディングブロック、色素前駆体、機能性反応ハンドル。

### 技術プラットフォーム

- [コンジュゲーション化学とリンカー](https://chemos.com/ja/technology-platforms/conjugation-chemistry-linkers): オリゴ、ペプチド、タンパク質、ペイロード、キレート剤、脂質を結ぶリンカーとハンドル。
- [クリック化学と生体直交化学](https://chemos.com/ja/technology-platforms/click-bioorthogonal-chemistry): 無銅クリック、tetrazine ライゲーション、CuAAC ハンドル、標識化学。
- [オリゴヌクレオチド修飾](https://chemos.com/ja/technology-platforms/oligonucleotide-modification): ASO、siRNA、guide RNA、aptamer、研究用オリゴの糖、塩基、骨格、末端、コンジュゲーション修飾。
- [ペプチド修飾と糖ペプチド](https://chemos.com/ja/technology-platforms/peptide-modification): 非天然アミノ酸、脂質化、PEG化、糖鎖化残基、ステープリング、コンジュゲーション。
- [ADC リンカー-ペイロード 化学](https://chemos.com/ja/technology-platforms/adc-linker-payload): 切断型/安定型 リンカー、親水性 スペーサー、選択的 反応性官能基、ペイロード-リンカー 中間体。
- [PROTAC / TPD ビルディングブロック](https://chemos.com/ja/technology-platforms/protac-tpd-building-blocks): CRBN/VHL 誘導体、リガンド-リンカー、二官能性中間体、リンカー ビルディングブロック。
- [放射性医薬品キレート剤](https://chemos.com/ja/technology-platforms/radiopharmaceutical-chelators): 大環状・非環状キレート剤、二官能性ハンドル、非放射性前駆体ビルディングブロック。
- [デリバリー用脂質材料](https://chemos.com/ja/technology-platforms/lipid-materials-delivery): イオン化脂質類似体、PEG 脂質、リン脂質、ステロール、リガンド脂質コンジュゲート。

### プロセス化学

- [フッ素化化学](https://chemos.com/ja/process-chemistry/fluorination): 含フッ素ビルディングブロック、フルオロアルキル基、含フッ素複素環のルート支援。
- [リン化学](https://chemos.com/ja/process-chemistry/phosphorus-chemistry): ホスホロアミダイト、ホスホネート誘導体、リン酸化試薬、含リン中間体。
- [硫黄化学](https://chemos.com/ja/process-chemistry/sulfur-chemistry): 硫化試薬、チオエーテル、スルホニル化合物、ジスルフィド、含硫リンカー。
- [キラル化学](https://chemos.com/ja/process-chemistry/chiral): キラル ビルディングブロック、分割戦略、不斉ルート、立体化学分析。
- [フローケミストリー](https://chemos.com/ja/process-chemistry/flow): 熱移動、混合、滞留時間制御が有効な反応に対するプロセス強化支援。
- [オリゴヌクレオチド合成](https://chemos.com/ja/process-chemistry/oligonucleotide-synthesis): 修飾モノマー、担体、硫化試薬、キャップ 類似体、関連するオリゴ合成入力物の支援。
- [PEG化とPEGリンカー合成](https://chemos.com/ja/process-chemistry/pegylation): PEG スペーサー、PEG脂質材料、PEGリンカー、ヘテロ二官能性PEGハンドル、精製計画。
- [スケールアップ支援](https://chemos.com/ja/process-chemistry/scale-up-support): 選定された特殊ビルディングブロックとコンジュゲーション試薬のプロジェクトバッチ支援。
- [分析法支援](https://chemos.com/ja/process-chemistry/analytical-method-support): 同一性、純度、不純物プロファイル、バッチ別技術資料に関する方法支援。
- [不純物プロファイリング](https://chemos.com/ja/process-chemistry/impurity-profiling): ルート開発、精製判断、プロジェクトバッチ比較のための不純物追跡。

### 用途

- [オリゴヌクレオチドプログラム](https://chemos.com/ja/applications/oligonucleotide-therapeutics): ASO、siRNA、guide RNA、アプタマー、研究/標識オリゴ向けビルディングブロックと修飾化学。
- [siRNA 研究プログラム](https://chemos.com/ja/applications/sirna-therapeutics): siRNA 研究ワークフロー向けの修飾モノマー、GalNAc リガンド、脂質コンジュゲーションハンドル、硫化試薬。
- [mRNA と LNP 材料](https://chemos.com/ja/applications/mrna-therapeutics): キャップアナログ、修飾NTP、イオン化脂質類似体、PEG脂質、補助脂質、脂質材料研究ツール。
- [標的化 LNP デリバリー材料](https://chemos.com/ja/applications/targeted-lnp): 標的化リガンド、リガンド-脂質 コンジュゲート、PEG脂質バリアント、イオン化脂質類似体、補助脂質。
- [肝細胞標的デリバリー](https://chemos.com/ja/applications/hepatocyte-targeted-delivery): GalNAc リガンド、オリゴコンジュゲーションハンドル、脂質コンジュゲート、肝臓指向デリバリー研究用リンカー。
- [肝外デリバリー](https://chemos.com/ja/applications/extrahepatic-delivery): 肝臓外デリバリー向けの代替デリバリーリガンド、脂質材料、コンジュゲーションハンドル。
- [ADC 開発関連化学](https://chemos.com/ja/applications/adc-development): リンカー、スペーサー、部位選択性ハンドル、キレート剤様結合モチーフ、ペイロード-リンカー 中間体支援。
- [PROTAC Discovery](https://chemos.com/ja/applications/protac-discovery): E3リガンド、リガンド-リンカー 中間体、PEG/アルキルリンカー、クリックハンドル、二官能性中間体。
- [放射性医薬品関連前駆体](https://chemos.com/ja/applications/radiopharmaceuticals): 冷状態キレート剤、二官能性ハンドル、PSMA/FAPI 中間体、非放射性前駆体ビルディングブロック。
- [標識とイメージング](https://chemos.com/ja/applications/labeling): 生体直交ハンドル、色素 結合、ビオチン化、表面・生体分子標識試薬。

### 技術資料、FAQ、参考文献

#### [DBCO と BCN の比較](https://chemos.com/ja/resources/dbco-vs-bcn)

無銅クリックハンドルを反応速度、立体性、親脂性、プロジェクト適合性で比較します。

- 質問: DBCOはいつ検討しますか？
- 回答: 具体的誘導体が化学、溶解、反応、精製、分析に適合する場合です。
- 質問: BCNはいつ検討しますか？
- 回答: 反応、thiol、安定性、精製、分析を確認し、骨格と誘導体が適合する場合です。
- 参考文献: [Visualizing Metabolically Labeled Glycoconjugates of Living Cells by Copper-Free and Fast Huisgen Cycloadditions](https://doi.org/10.1002/anie.200705456); [Readily Accessible Bicyclononynes for Bioorthogonal Labeling and Three-Dimensional Imaging of Living Cells](https://doi.org/10.1002/anie.201003761); [A Simple Method for Enhancing the Bioorthogonality of Cyclooctyne Reagent](https://pubs.rsc.org/en/content/articlelanding/2016/cc/c6cc01321j); [Evaluation of Dibenzocyclooctyne and Bicyclononyne Click Reaction on Azido-Functionalized Antifouling Polymer Brushes via Microspotting](https://doi.org/10.1002/admi.202102325)

#### [SPAAC と IEDDA の比較](https://chemos.com/ja/resources/spaac-vs-iedda)

生体直交コンジュゲーションに用いる azide-cycloalkyne SPAAC と tetrazine-歪み dienophile IEDDA の実務比較。

- 質問: 主な選択因子は何ですか？
- 回答: 正確な反応対が利用可能な時間内に必要転化率へ達し、導入済みの両 反応性官能基 が全工程で安定かつ適合することです。
- 質問: 両戦略を比較または組み合わせられますか？
- 回答: 可能ですが、実系で交差反応、安定性、導入順序、精製、分析上の識別を示す必要があります。
- 参考文献: [A Strain-Promoted [3 + 2] Azide–Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems](https://pubs.acs.org/doi/10.1021/ja044996f); [Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels–Alder Reactivity](https://pubs.acs.org/doi/10.1021/ja8053805); [Uncovering the Key Role of Distortion in Bioorthogonal Tetrazine Tools That Defy the Reactivity/Stability Trade-Off](https://pubs.acs.org/doi/10.1021/jacs.2c01056); [Trans-Cyclooctene Isomerization Catalyzed by Thiamine Degradation Products in Cell Culture Media](https://pubs.acs.org/doi/10.1021/acsomega.5c01780)

#### [DOTA、NOTA、DFO の比較](https://chemos.com/ja/resources/dota-vs-nota-vs-dfo)

対象金属、錯形成条件、ベクター 耐性、二官能性誘導体、分析計画で三系統を比較します。

- 質問: 万能なキレート剤はありますか？
- 回答: ありません。金属、誘導体、条件、ベクター、結合、必要寿命、精製、分析証拠で適合性を判断します。
- 質問: CHEMOS は放射性材料を供給しますか？
- 回答: いいえ。選定した 非放射性・非放射性 キレート剤、二官能性誘導体、中間体、前駆体に注力します。
- 参考文献: [Comparison of Macrocyclic and Acyclic Chelators for Gallium-68 Radiolabelling](https://doi.org/10.1039/C7RA09076E); [Side by Side Comparison of NOTA and DOTA for Conjugation Efficiency, Gallium-68 Labeling, and In Vivo Biodistribution of Anti-Mesothelin sdAb A1-His](https://doi.org/10.1186/s41181-025-00380-5); [A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89](https://doi.org/10.1021/acs.inorgchem.0c01629); [A First-in-Class Dual-Chelator Theranostic Agent Designed for Use with Imaging-Therapy Radiometal Pairs of Different Elements](https://doi.org/10.1039/D4SC02851A)

#### [イオン化脂質設計](https://chemos.com/ja/resources/ionizable-lipid-design)

正確な構造、製剤中の役割、搭載物、実験経路、分解仮説、物料管理で類似体を定義します。

- 質問: カスタム脂質類似体には何が必要ですか？
- 回答: 正確な構造または管理された系列、製剤と 搭載物、量、仕様、分析、研究条件、顧客提示の IP/FTO 制約です。
- 質問: 命名脂質は権利や同等性能を意味しますか？
- 回答: いいえ。構造参照のみで、権利、FTO、同一組成、同等性能を意味しません。
- 参考文献: [Rational Design of Cationic Lipids for siRNA Delivery](https://doi.org/10.1038/nbt.1602); [Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics](https://doi.org/10.1038/mt.2013.124); [Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity](https://doi.org/10.1038/ncomms5277); [Ionization and Structural Properties of mRNA Lipid Nanoparticles Influence Expression in Intramuscular and Intravascular Administration](https://doi.org/10.1038/s42003-021-02441-2)

#### [PEG脂質の選択](https://chemos.com/ja/resources/peg-lipid-selection)

Anchor、PEG 定義、末端、配合比、保持・脱離仮説、分析管理で選択します。

- 質問: 注文前に何を合わせるべきですか？
- 回答: Anchor、リンカー、PEG 定義、末端、仕様、比率、工程、役割、分析です。
- 質問: 末端機能はカスタムできますか？
- 回答: 構造、反応基含量、量、安定性、用途、分析が明確なら評価できます。
- 参考文献: [Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles](https://doi.org/10.1038/mtna.2013.66); [Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method](https://doi.org/10.3390/pharmaceutics15020597); [Role of PEGylated Lipid in Lipid Nanoparticle Formulation for In Vitro and In Vivo Delivery of mRNA Vaccines](https://doi.org/10.1016/j.jconrel.2025.01.071); [The Impact of Polyethylene Glycol Lipid Anchors on the Physicochemical Properties, Protein Corona, Function, and Biodistribution of Lipid Nanoparticles](https://doi.org/10.1021/acsnano.5c19757)

#### [GalNAc と脂質コンジュゲーションの比較](https://chemos.com/ja/resources/galnac-vs-lipid-conjugation)

受容体指向多価 GalNAc と構造依存 脂質 コンジュゲーション を異なる戦略として比較します。

- 質問: 同じオリゴで両方使えますか？
- 回答: 両方で研究できますが、scaffold、リンカー、site、精製、投与量、対照、評価は各 コンジュゲート ごとに定義します。
- 質問: 最初に必要な情報は？
- 回答: 生物経路、oligo 配置図、正確な リガンド、site、リンカー、方法、仕様、対照です。
- 参考文献: [siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes](https://doi.org/10.1021/cb501028c); [Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands](https://doi.org/10.1124/jpet.115.230300); [Hydrophobicity Drives the Systemic Distribution of Lipid-Conjugated siRNAs via Lipid Transport Pathways](https://doi.org/10.1093/nar/gky1232); [Diverse Lipid Conjugates for Functional Extra-Hepatic siRNA Delivery In Vivo](https://doi.org/10.1093/nar/gky1239)

#### [PROTACリンカー選択](https://chemos.com/ja/resources/protac-linker-selection)

両 リガンド、結合ベクトル、三元複合体 geometry、配座、透過性、合成、測定 から系列を設計します。

- 質問: リンカー長だけで十分ですか？
- 回答: 不十分です。リガンド、結合ベクトル、組成、構象、透過性、安定性、複合体、合成、測定 が必要です。
- 質問: 事前機能化 リガンド-リンカー は有用ですか？
- 回答: リガンド、立体化学、結合ベクトル、反応性官能基、方向、カップリング が一致すれば合成を簡略化しますが、系列と試験は必要です。
- 参考文献: [Structural Basis of PROTAC Cooperative Recognition for Selective Protein Degradation](https://doi.org/10.1038/nchembio.2329); [Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation](https://doi.org/10.1021/acsmedchemlett.2c00124); [Linker-Dependent Folding Rationalizes PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.2c00877); [Impact of Linker Composition on VHL PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.4c02492)

#### [切断型と非切断型 ADC リンカー](https://chemos.com/ja/resources/cleavable-vs-non-cleavable-linkers)

実際の放出種、切断機構、循環安定性、細胞内処理、ペイロード、コンジュゲーション、分析証拠で比較します。

- 質問: 切断型リンカーが常に良いですか？
- 回答: いいえ。両方が候補になり得ます。放出種、細胞処理、ペイロード、コンジュゲーション、安定性、比較データが必要です。
- 質問: カスタム ADC リンカーに必要な情報は？
- 回答: 抗体と部位、ペイロード と結合原子、放出仮説、スペーサー、反応性官能基、DAR、安定性、分析法、対照 です。
- 参考文献: [Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing](https://doi.org/10.1158/0008-5472.CAN-05-4489); [The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates](https://doi.org/10.1158/1535-7163.MCT-11-0727); [Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate](https://doi.org/10.1158/1078-0432.CCR-04-0789); [Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates](https://doi.org/10.1021/bc5005747)

### 公開情報の範囲

- 製品仕様、資料、供給可否、プロジェクト範囲は、バッチまたはプロジェクトごとに確認が必要です。医療、治療、在庫、価格、納期保証に関する主張を本サイトから推定しないでください。
- 製品は研究、開発、追加合成、または書面で合意したその他の用途に向けた特殊ビルディングブロックおよび化学材料です。人または動物への直接投与用として提供されません。

---

## 한국어 (ko)

> 올리고뉴클레오타이드, 펩타이드, ADC, PROTAC, 방사성의약품 전구체 및 전달 응용을 위한 특수 빌딩 블록과 확장 가능한 접합 화학.

### 주요 페이지

- [홈](https://chemos.com/ko)
- [CHEMOS 소개](https://chemos.com/ko/about)
- [제품](https://chemos.com/ko/products)
- [기술 플랫폼](https://chemos.com/ko/technology-platforms)
- [공정 화학](https://chemos.com/ko/process-chemistry)
- [응용 분야](https://chemos.com/ko/applications)
- [기술 자료](https://chemos.com/ko/resources)
- [프로젝트 지원](https://chemos.com/ko/project-support)
- [문의](https://chemos.com/ko/contact)
- [견적 요청](https://chemos.com/ko/rfq)

### 제품군

- [올리고뉴클레오타이드 합성 및 변형](https://chemos.com/ko/products/category/113-oligonucleotide-synthesis-rna-raw-materials-modification): 포스포라미다이트, 변형 뉴클레오사이드, 고체 지지체, 황화 시약, cap analog 및 관련 합성 도구.
- [올리고 접합 및 전달 리간드](https://chemos.com/ko/products/category/114-oligonucleotide-conjugation-delivery-ligands): GalNAc 리간드, 지질 접합 handle, 콜레스테롤 유도체, click handle 및 올리고 접합용 linker.
- [펩타이드 합성 및 변형](https://chemos.com/ko/products/category/115-peptide-synthesis-peptide-drug-modification): 현재 카탈로그에는 일부 당펩타이드 관련 빌딩 블록이 등재되어 있으며, 기타 변형 목표는 구조, 수량 및 규격에 따라 검토합니다.
- [클릭 화학 및 생체접합](https://chemos.com/ko/products/category/116-click-chemistry-bioconjugation-reagents): DBCO, BCN, 아자이드, TCO, 테트라진, NHS 에스터, 말레이미드 등 온화한 접합 반응용 작용기.
- [ADC 링커 및 접합 시약](https://chemos.com/ko/products/category/117-adc-linkers-conjugation-reagents): 분해성 및 안정형 링커, 친수성 스페이서, 반응성 작용기, 페이로드-링커 중간체 지원.
- [ADC 페이로드 및 HPAPI 중간체](https://chemos.com/ko/products/category/118-adc-payloads-hpapi-intermediates): 정확한 구조, 수량, 취급 제한, 규격 및 분석 요구사항을 기준으로 검토하는 프로젝트별 페이로드 및 고활성 중간체 요청.
- [PROTAC, E3 리간드 및 근접 유도 빌딩 블록](https://chemos.com/ko/products/category/119-protac-e3-ligands-proximity-inducing-building-blocks): E3 리간드 유도체, 기능화 linker, 이기능성 중간체 및 PROTAC·근접 유도 연구용 기타 빌딩 블록.
- [방사성의약품 Chelator 및 전구체](https://chemos.com/ko/products/category/120-radiopharmaceutical-chelators-precursors-targeting-ligands): DOTA, NOTA, DFO, DTPA, 이중기능 chelator 및 imaging/radioligand 프로그램용 비방사성 전구체 빌딩 블록.
- [LNP 및 전달 지질](https://chemos.com/ko/products/category/121-lnp-nucleic-acid-delivery-lipids): 이온화 지질 유사체, PEG 지질, 보조 인지질, 콜레스테롤 유도체 및 기능성 전달 지질 소재.
- [형광 표지, 바이오틴화 및 프로브](https://chemos.com/ko/products/category/122-fluorescent-labeling-biotinylation-probes): 표지 및 검출 연구용 형광·발색 프로브, 바이오틴화 빌딩 블록, 염료 전구체 및 기능성 반응 작용기.

### 기술 플랫폼

- [접합 화학 및 링커](https://chemos.com/ko/technology-platforms/conjugation-chemistry-linkers): Oligo, 펩타이드, protein, 페이로드, 킬레이트제 및 지질를 연결하는 링커와 기능성 작용기.
- [클릭 및 생체직교 화학](https://chemos.com/ko/technology-platforms/click-bioorthogonal-chemistry): 무구리 클릭, tetrazine 연결 반응, CuAAC 작용기 및 표지 화학.
- [올리고뉴클레오타이드 변형](https://chemos.com/ko/technology-platforms/oligonucleotide-modification): ASO, siRNA, guide RNA, aptamer 및 연구용 oligo의 sugar, base, 골격, terminal 및 접합 변형.
- [펩타이드 변형 및 당펩타이드](https://chemos.com/ko/technology-platforms/peptide-modification): 비천연 아미노산, 지질화, PEGylation, 당화 잔기, 스테이플링 및 접합.
- [ADC 링커-페이로드 화학](https://chemos.com/ko/technology-platforms/adc-linker-payload): 분해성/안정 링커, 친수성 스페이서, 선택적 작용기 및 페이로드-링커 중간체.
- [PROTAC / TPD 빌딩 블록](https://chemos.com/ko/technology-platforms/protac-tpd-building-blocks): CRBN/VHL 유도체, 리간드-링커, 이중기능성 중간체 및 링커 빌딩 블록.
- [방사성의약품 킬레이터](https://chemos.com/ko/technology-platforms/radiopharmaceutical-chelators): 거대고리·비고리 킬레이터, 이중기능 핸들 및 비방사성 전구체 빌딩 블록.
- [전달용 지질 소재](https://chemos.com/ko/technology-platforms/lipid-materials-delivery): 이온화 지질 유사체, PEG 지질, 인지질, 스테롤 및 리간드-지질 접합체.

### 공정 화학

- [불소화 화학](https://chemos.com/ko/process-chemistry/fluorination): 불소화 빌딩 블록, fluoroalkyl 기 및 불소화 hetero주기 경로 지원.
- [인 화학](https://chemos.com/ko/process-chemistry/phosphorus-chemistry): 포스포아미다이트, phosphonate 유도체, phosphorylation 시약 및 인 함유 중간체.
- [황 화학](https://chemos.com/ko/process-chemistry/sulfur-chemistry): 황화 시약, thioether, sulfonyl 화합물, disulfide 및 황 함유 링커.
- [키랄 화학](https://chemos.com/ko/process-chemistry/chiral): 키랄 빌딩 블록, resolution 전략, 비대칭 경로 및 입체화학 분석.
- [Flow 화학](https://chemos.com/ko/process-chemistry/flow): 열전달, 혼합 또는 residence time 제어가 유리한 반응을 위한 공정 강화 지원.
- [올리고뉴클레오타이드 합성](https://chemos.com/ko/process-chemistry/oligonucleotide-synthesis): 변형 단량체, 고체 지지체, 황화 시약, 캡 유사체 및 관련 oligo 합성 원료 지원.
- [PEGylation 및 PEG 링커 합성](https://chemos.com/ko/process-chemistry/pegylation): PEG 스페이서, PEG 지질 소재, PEG 링커, hetero이중기능성 PEG 작용기 및 정제 계획.
- [규모 확대 지원](https://chemos.com/ko/process-chemistry/scale-up-support): 선정된 특수 빌딩 블록과 접합 시약을 위한 프로젝트 배치 규모 확대 지원.
- [분석법 지원](https://chemos.com/ko/process-chemistry/analytical-method-support): 동일성, 순도, im순도 profiling 및 배치별 기술 문서에 대한 분석법 지원.
- [불순물 프로파일링](https://chemos.com/ko/process-chemistry/impurity-profiling): 경로 개발, 정제 결정 및 프로젝트 배치 비교성을 위한 불순물 추적.

### 응용 분야

- [올리고뉴클레오타이드 프로그램](https://chemos.com/ko/applications/oligonucleotide-therapeutics): ASO, siRNA, guide RNA, aptamer 및 연구/표지 oligo 프로젝트용 빌딩 블록과 변형 화학.
- [siRNA 연구 프로그램](https://chemos.com/ko/applications/sirna-therapeutics): siRNA 연구 작업 흐름용 변형 단량체, GalNAc 리간드, 지질 접합 작용기 및 황화 시약.
- [mRNA 및 LNP 소재](https://chemos.com/ko/applications/mrna-therapeutics): 캡 유사체, 변형 NTP, 이온화 지질 유사체, PEG 지질, 보조 지질 및 지질 소재 연구 도구.
- [표적 LNP 전달 소재](https://chemos.com/ko/applications/targeted-lnp): 표적 리간드, 리간드-지질 접합체, PEG 지질 변이체, 이온화 지질 유사체 및 helper-지질 소재.
- [간세포 표적 전달](https://chemos.com/ko/applications/hepatocyte-targeted-delivery): 간 지향 전달 연구용 GalNAc 리간드, oligo 접합 작용기, 지질 접합체 및 링커 선택.
- [간외 전달](https://chemos.com/ko/applications/extrahepatic-delivery): 간 지향 프로그램 외 전달을 위한 대체 리간드, 지질 소재 및 접합 작용기.
- [ADC 개발 관련 화학](https://chemos.com/ko/applications/adc-development): 링커, 스페이서, site-selective 작용기, 킬레이트제-like attachment motif 및 페이로드-링커 중간체 지원.
- [PROTAC Discovery](https://chemos.com/ko/applications/protac-discovery): E3 리간드, 리간드-링커 중간체, PEG/알킬 링커, 클릭 작용기 및 이중기능성 중간체.
- [방사성의약품 관련 전구체](https://chemos.com/ko/applications/radiopharmaceuticals): 비방사성 킬레이트제, 이중기능성 작용기, PSMA/FAPI 중간체 및 비방사성 전구체 빌딩 블록.
- [표지 및 이미징](https://chemos.com/ko/applications/labeling): 생체직교 작용기, 형광 염료 연결, 비오틴ylation 및 표면·생체분자 표지 시약.

### 기술 자료, FAQ 및 참고 문헌

#### [DBCO vs BCN](https://chemos.com/ko/resources/dbco-vs-bcn)

두 가지 무구리 클릭 작용기을 반응 속도, 입체 프로파일, 친지질성 및 프로젝트 적합성으로 비교합니다.

- 질문: DBCO는 언제 고려하나요?
- 답변: 정확한 유도체가 화학, 용해, 반응, 정제 및 분석에 맞을 때입니다.
- 질문: BCN은 언제 고려하나요?
- 답변: 반응, 티올, 안정성, 정제 및 분석 확인 후 골격과 유도체가 맞을 때입니다.
- 참고 문헌: [Visualizing Metabolically Labeled Glycoconjugates of Living Cells by Copper-Free and Fast Huisgen Cycloadditions](https://doi.org/10.1002/anie.200705456); [Readily Accessible Bicyclononynes for Bioorthogonal Labeling and Three-Dimensional Imaging of Living Cells](https://doi.org/10.1002/anie.201003761); [A Simple Method for Enhancing the Bioorthogonality of Cyclooctyne Reagent](https://pubs.rsc.org/en/content/articlelanding/2016/cc/c6cc01321j); [Evaluation of Dibenzocyclooctyne and Bicyclononyne Click Reaction on Azido-Functionalized Antifouling Polymer Brushes via Microspotting](https://doi.org/10.1002/admi.202102325)

#### [SPAAC vs IEDDA](https://chemos.com/ko/resources/spaac-vs-iedda)

생체직교 접합을 위한 azide-cycloalkyne SPAAC와 tetrazine-strained dienophile IEDDA의 실무 비교.

- 질문: 주요 선택 요소는 무엇인가요?
- 답변: 정확한 반응 쌍이 가능한 시간 안에 필요한 전환율에 도달하고 설치된 두 작용기이 전체 공정에서 안정하고 호환되는지입니다.
- 질문: 두 전략을 비교하거나 조합할 수 있나요?
- 답변: 가능하지만 실제 시스템에서 교차반응, 안정성, 설치 순서, 정제 및 분석적 구분을 입증해야 합니다.
- 참고 문헌: [A Strain-Promoted [3 + 2] Azide–Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems](https://pubs.acs.org/doi/10.1021/ja044996f); [Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels–Alder Reactivity](https://pubs.acs.org/doi/10.1021/ja8053805); [Uncovering the Key Role of Distortion in Bioorthogonal Tetrazine Tools That Defy the Reactivity/Stability Trade-Off](https://pubs.acs.org/doi/10.1021/jacs.2c01056); [Trans-Cyclooctene Isomerization Catalyzed by Thiamine Degradation Products in Cell Culture Media](https://pubs.acs.org/doi/10.1021/acsomega.5c01780)

#### [DOTA vs NOTA vs DFO](https://chemos.com/ko/resources/dota-vs-nota-vs-dfo)

목표 금속, 착물 형성 조건, 벡터 내성, 이중기능 유도체 및 분석 계획으로 세 계열을 비교합니다.

- 질문: 보편적으로 최선인 킬레이트제가 있나요?
- 답변: 아니요. 금속, 유도체, 조건, 벡터, 연결, 필요한 수명, 정제 및 분석 근거가 적합성을 결정합니다.
- 질문: CHEMOS는 방사성 물질을 공급하나요?
- 답변: 아니요. 선정된 비방사성 킬레이트제, 이중기능 유도체, 중간체 및 전구체에 집중합니다.
- 참고 문헌: [Comparison of Macrocyclic and Acyclic Chelators for Gallium-68 Radiolabelling](https://doi.org/10.1039/C7RA09076E); [Side by Side Comparison of NOTA and DOTA for Conjugation Efficiency, Gallium-68 Labeling, and In Vivo Biodistribution of Anti-Mesothelin sdAb A1-His](https://doi.org/10.1186/s41181-025-00380-5); [A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89](https://doi.org/10.1021/acs.inorgchem.0c01629); [A First-in-Class Dual-Chelator Theranostic Agent Designed for Use with Imaging-Therapy Radiometal Pairs of Different Elements](https://doi.org/10.1039/D4SC02851A)

#### [이온화 지질 설계](https://chemos.com/ko/resources/ionizable-lipid-design)

정확한 구조, 제형 역할, 탑재 물질, 실험 경로, 분해 가설 및 소재 제어로 유사체를 정의합니다.

- 질문: 맞춤형 지질 유사체 범위 설정에 필요한 정보는?
- 답변: 정확한 구조 또는 통제된 계열, 제형과 탑재 물질, 양, 규격, 분석, 연구 맥락 및 고객 제공 IP/FTO 제약입니다.
- 질문: 명명된 지질가 권리나 동등 성능을 의미하나요?
- 답변: 아니요. 구조 참고일 뿐 권리, FTO, 동일 조성 또는 동등 성능을 의미하지 않습니다.
- 참고 문헌: [Rational Design of Cationic Lipids for siRNA Delivery](https://doi.org/10.1038/nbt.1602); [Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics](https://doi.org/10.1038/mt.2013.124); [Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity](https://doi.org/10.1038/ncomms5277); [Ionization and Structural Properties of mRNA Lipid Nanoparticles Influence Expression in Intramuscular and Intravascular Administration](https://doi.org/10.1038/s42003-021-02441-2)

#### [PEG 지질 선택](https://chemos.com/ko/resources/peg-lipid-selection)

앵커, PEG 정의, 말단, 제형 비율, 유지·탈리 가설 및 분석 제어로 선택합니다.

- 질문: 주문 전 무엇을 맞춰야 하나요?
- 답변: 앵커, 링커, PEG 정의, 말단, 규격, 비율, 공정, 역할 및 분석입니다.
- 질문: Terminal functionality를 맞춤화할 수 있나요?
- 답변: 구조, 반응기 함량, 양, 안정성, 용도 및 분석이 정의되면 평가할 수 있습니다.
- 참고 문헌: [Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles](https://doi.org/10.1038/mtna.2013.66); [Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method](https://doi.org/10.3390/pharmaceutics15020597); [Role of PEGylated Lipid in Lipid Nanoparticle Formulation for In Vitro and In Vivo Delivery of mRNA Vaccines](https://doi.org/10.1016/j.jconrel.2025.01.071); [The Impact of Polyethylene Glycol Lipid Anchors on the Physicochemical Properties, Protein Corona, Function, and Biodistribution of Lipid Nanoparticles](https://doi.org/10.1021/acsnano.5c19757)

#### [GalNAc vs 지질 접합](https://chemos.com/ko/resources/galnac-vs-lipid-conjugation)

수용체 지향 다가 GalNAc와 구조 의존 지질 접합을 서로 다른 전략으로 비교합니다.

- 질문: 같은 oligo가 두 경로를 모두 사용할 수 있나요?
- 답변: 둘 다 연구할 수 있지만 골격, 링커, site, 정제, 투여량, 대조 및 평가는 각 접합체별로 정의합니다.
- 질문: 먼저 필요한 제품 정보는?
- 답변: 생물 경로, oligo 배치도, 정확한 리간드, site, 링커, 방법, 규격 및 대조입니다.
- 참고 문헌: [siRNA Conjugates Carrying Sequentially Assembled Trivalent N-Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing In Vivo in Hepatocytes](https://doi.org/10.1021/cb501028c); [Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands](https://doi.org/10.1124/jpet.115.230300); [Hydrophobicity Drives the Systemic Distribution of Lipid-Conjugated siRNAs via Lipid Transport Pathways](https://doi.org/10.1093/nar/gky1232); [Diverse Lipid Conjugates for Functional Extra-Hepatic siRNA Delivery In Vivo](https://doi.org/10.1093/nar/gky1239)

#### [PROTAC 링커 선택](https://chemos.com/ko/resources/protac-linker-selection)

두 리간드, 결합 방향, 삼원 복합체 기하, 구조 형태, 투과성, 합성 및 분석로 계열를 설계합니다.

- 질문: 링커 길이만으로 충분한가요?
- 답변: 아니요. 리간드, 결합 방향, 조성, 구조, 투과성, 안정성, 복합체, 합성 및 분석가 필요합니다.
- 질문: Pre-functionalized 리간드-링커가 반복을 줄이나요?
- 답변: 리간드, 입체화학, 결합 방향, 작용기, 방향 및 결합이 맞으면 합성을 단순화하지만 계열와 시험은 필요합니다.
- 참고 문헌: [Structural Basis of PROTAC Cooperative Recognition for Selective Protein Degradation](https://doi.org/10.1038/nchembio.2329); [Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation](https://doi.org/10.1021/acsmedchemlett.2c00124); [Linker-Dependent Folding Rationalizes PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.2c00877); [Impact of Linker Composition on VHL PROTAC Cell Permeability](https://doi.org/10.1021/acs.jmedchem.4c02492)

#### [분해성 vs 비분해성 ADC 링커](https://chemos.com/ko/resources/cleavable-vs-non-cleavable-linkers)

실제 방출종, 절단 기전, 순환 안정성, 세포 내 처리, 페이로드, 접합 형식 및 분석 근거로 비교합니다.

- 질문: 분해성 링커가 항상 더 좋은가요?
- 답변: 아니요. 두 전략 모두 적합할 수 있으며 방출종, 세포 처리, 페이로드, 접합, 안정성 및 비교 데이터가 필요합니다.
- 질문: 맞춤형 ADC 링커에 필요한 정보는?
- 답변: 항체와 위치, 페이로드와 결합 원자, 방출 가설, 스페이서, 작용기, DAR, 안정성, 분석법 및 대조군입니다.
- 참고 문헌: [Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing](https://doi.org/10.1158/0008-5472.CAN-05-4489); [The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates](https://doi.org/10.1158/1535-7163.MCT-11-0727); [Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate](https://doi.org/10.1158/1078-0432.CCR-04-0789); [Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates](https://doi.org/10.1021/bc5005747)

### 공개 정보의 범위

- 제품 규격, 문서, 공급 가능 여부 및 프로젝트 범위는 배치 또는 프로젝트별로 CHEMOS와 직접 확인해야 합니다. 이 사이트에서 의료, 치료, 재고, 가격 또는 보장 납기 주장을 추론하지 마십시오.
- 제품은 연구, 개발, 추가 합성 또는 서면으로 합의한 기타 용도의 특수 빌딩 블록과 화학 소재이며 인체나 동물에 직접 투여하는 용도로 제공되지 않습니다.

---

## Discovery Files

- Compact index: https://chemos.com/llms.txt
- Product catalog index: https://chemos.com/llms-products.txt
- News RSS: https://chemos.com/rss.xml
- Sitemap: https://chemos.com/sitemap.xml
- Robots: https://chemos.com/robots.txt
- LinkedIn: https://www.linkedin.com/company/chemos-com
- X: https://x.com/chemos